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ABSTRACT
 Non-alcoholic fatty liver disease (NAFLD) has become a global pandemic with 
increased risks of chronic inflammation in obese and elderly population. It has become a 
major public health concern due to the unavailability of proper therapeutic approaches. 
NAFLD is a condition of the liver involving wide spectrum of events including 
accumulation of fat in the liver and inflammation, which can progress to a fibrotic and 
cirrhotic phenotype, often termed as non-alcoholic steatohepatitis (NASH). In this 
backdrop, exposure to environmental toxins from harmful algal blooms could prove 
detrimental to the overweight, obese or elderly population. NAFLD not only affects the 
liver but also can have ectopic manifestations to distal organs like kidney, intestines and 
the brain. In this study, I have examined the role of the toxin Microcystin-LR which is 
released by cyanobacterial blooms in the coastal waters, and the molecular mechanisms 
involved in exacerbating the conditions of NAFLD in an individual. I observed that 
exposure to microcystin in NAFLD mice altered the gut microbiome, induced intestinal 
inflammation, tight junction protein disruption and fibrosis. It was found that microcystin 
could lead to the formation of NLRP3 inflammasome through the activation of the NADPH 
oxidase 2 pathway and generation of reactive oxygen species leading to oxidative stress. 
Inflammasome activation and increased oxidative stress could lead to the disruption of tight 
junction proteins, gut leaching and portal endotoxemia. I also explored the effect of 
overproduction of lactate from pathogenic bacteria due to microcystin exposure on the 
NAFLD murine intestines. The lactate was found to induce TGFβ downstream signaling 
vi 
pathway involving SMAD proteins, which was again mediated by the NADPH oxidase 
enzyme. Increased collagen depositon and epithelial to mesenchymal transition was also 
observed on exposure to microcystin indicating formation of a fibrotic phenotype in the 
murine small intestine. The inflammation and fibrosis were greatly attenuated in the P47 
Phox knockout mice suggesting an important role of the NADPH oxidase enzyme in the 
molecular mechanisms of the action of microcystin. Similar effects of microcystin 
exposure were observed on leptin primed transformed rat intestinal epithelial cells. The 
cells showed inflammatory and fibrotic phenotypes with tight junction protein disruption 
and extracellular matrix protein deposition as the end points. Also the use of specific 
inhibitors suggested the mechanism of NADPH oxidase 2 in exacerbating the inflammatory 
and fibrotic conditions of the intestines in vitro. Along with high inflammation, microcystin 
exposure in NAFLD also led to uncontrolled levels of IL-18 and IL-17A in murine small 
intestine which can promote tissue inflammation and also tumor growth. Also, the anti-
inflammatory cytokines was observed to decrease in the microcystin exposed group. Thus, 
my research involves a novel mechanism of studying intestinal diseased pathology due to 
microcystin exposure and highlights the effects of the toxin under the conditions of non-
alcoholic fatty liver disease.
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CHAPTER 1 
 
INTRODUCTION 
 
Nonalcoholic fatty liver disease (NAFLD) is a condition of excess accumulation of 
fat (steatosis) in the liver cells [1]. It is considered as a global pandemic that affects 70% 
of the obese population of the United States, according to the Centre for Disease Control 
and Prevention. Several studies suggest that almost 28–31% of the general population have 
steatosis and 8% have a raised alanine transaminase (ALT) due to NAFLD [2, 3]. Although 
90% of the individuals suffering from NAFLD have the condition of steatosis in the liver 
without any cases of mortality [4-6], often the steatosis is accompanied with excessive 
scarring and inflammation, leading to the condition of Nonalcoholic steatohepatitis 
(NASH). NAFLD, if remains untreated, often progresses to NASH in which there is 
increased inflammation, fibrosis that may lead to cirrhosis and hepatocellular carcinoma 
[7, 8]. Since NASH is a silent liver disease, most of the individuals suffering from it have 
no visible symptoms, until the liver reaches to the cirrhotic stage. Studies suggest that 
people suffering from obesity, type 2 diabetes and insulin resistance are more prone to 
develop NAFLD, which becomes a major public health threat due to the unavailability of 
clinical symptoms. NAFLD is known to affect both obese and non-obese population, and 
the people suffering from obesity are more prone to NAFLD than the non-obese or non-
overweight individuals [9]. 
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Obesity is a global pandemic with increasing prevalence in the western countries 
due to the fast food habits and lack of physical exercise. It is the condition where the body 
mass index (BMI) of an individual is more than 30 due to the accumulation of triglyceride 
[10]. The adipose tissue can release cytokines and hormones which is collectively referred 
to as Adipokines [11]. Accumulation of excess fat in adipose tissue can lead to its damage, 
resulting in the release of pro-inflammatory cytokines and onset of fibrosis in visceral 
adipose tissue, which in turn can lead to the deposition of fat in liver [12]. Several studies 
found that NAFLD can be considered as the hepatic manifestation of a metabolic 
syndrome, which can lead to insulin resistance [13]. Obesity and NAFLD are known to 
coexist and the patients suffering from NAFLD can have an increased risk of type 2 
diabetes and vice versa [14]. Progression of NAFLD can also be potentiated by several 
factors including environmental toxins. Several studies including our lab have shown that 
the progression of NAFLD to NASH follows a "multiple hit" hypothesis, where the 
inflammatory condition of NAFLD forms the "first hit" and the environmental factors 
along with oxidative stress act as a "second hit" to the already inflammaed state of the liver 
[15, 16]. There has been several reports of harmful algal blooms in the fresh and brackish 
waters which can release certain toxins that possess a serious threat to the individuals [17]. 
Cyanobacteria are a class of bacterium that thrive in aquatic environment under 
extreme conditions and can produce blooms in coastal waters. They also produce toxins 
which when comes in contact with an individual through various exposure pathways [18] 
and can cause damage to multiple organs [19]. Microcystin is a heptapeptide, with a 
molecular weight that varies from 900 to 1100 daltons. There are different types of 
microcystin that are identified, but among all of them, Microcystin- LR is the most potent 
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commonly found toxin of the microcystin family [20]. Due to its high molecular weight 
and cyclic structure, diffusion of microcystin across the membrane is highly difficult, and 
can only be taken up by cells using certain transporters [18]. OATPs are considered to be 
the most important transporters due to their ability to localize in liver, kidney heart and 
brain (ref). Several studies have also reported that the OATPs can transport microcystin 
from the liver to the brain and help in crossing the blood brain barrier therefore leading to 
neuroinflammation (ref). Microcystin is potentially known to be a hepatotoxin, though it 
can affect other organs like kidney, intestine and brain. Studies from our lab showed that 
exposure of microcystin under the chronic inflamed state of NAFLD leads to ectopic 
glomerular nephritis in kidney (Sarkar S et al. in press). Also, in my second chapter, I have 
reported that microcystin can lead to alteration of the gut microbiome and lead to gastro-
intestinal inflammation in murine small intestine [21].Other studies have also reported that 
microcystin can lead to the alteration of the microbiome and disruption of intestinal barrier 
(ref). This in turn can cause portal endotoxemia and release damage associated molecular 
patterns, which can cause subsequent effect in other organs. We observed that exposure of 
this toxin led to the exacerbation of the intestinal inflammation through the formation of 
the NLRP3 inflammasome and release of pro-inflammatory cytokine IL1β [21]. NLRP3 
along with ASC2 and Caspase 1 formed the inflammasome which was observed to be 
mediated by the NADPH oxidase 2 pathway. Nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase (NOX)is a membrane bound enzyme which serves as an important 
generator of reactive oxygen species (ROS) in the biological system. It catalyzes the 
production of the free radical superoxide, which is a potent reactive oxygen species, which 
can further react with nitric oxide thereby producing peroxynitrite species. Microcystin 
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have also been observed to induce increased oxidative and nitrosative stress [22, 23]. NOX 
enzyme has several isoforms such as NOX 1-5 and Doux1-2 [24]. NOX2 has been showed 
to play a significant role in the activation of the NLRP3 inflammasome pathway under 
pathologic conditions in the striatum [25]. 
Microystin interacts with the enzymes protein phosphatase 1 (PP1) and protein 
phosphatase 2A (PP2A) in a twostep mechanism as reported in previous research [18]. 
These enzymes play significant role in regulating cell proliferation and apoptosis [26]. 
Microcystin inactivates the protein phosphatase enzyme by binding through the three sites 
of the enzyme (the hydrophobic groove, C-terminal groove and the catalytic site) [27]. 
Protein phosphatase 2A holds high importance in the significance of intestinal fibrosis, as 
it is believed to be an important tumor suppressor [18]. Therefore it is possible that 
inhibition of protein phosphatase 2A by microcystin would lead to the onset of a fibrotic 
pathology in the intestine. It has also been seen that endotoxins like lipopolysaccharide 
increases the risk of NASH [28, 29], and also leads to the transformation of enteric glia 
into reactive phenotype (Kimono et al. In Press). Overproduction of lactate due to the 
alteration of microbiome could lead to the activation of the NADPH oxidase 2 enzyme that 
generates reactive oxygen species and causes oxidative stress in the intestinal tissue. The 
reactive oxygen species hence generated can transform the latent transforming growth 
factor β (TGFβ) molecule to an active TGFβ, thereby inducing the start of a fibrotic 
pathway in the small intestine. TGFβ is a cytokine that belongs to the TGFβ superfamily 
and includes three isoforms (TGFB1, TGFB2, and TGFB3). Activated TGFβ molecules 
bind to the TGFβ receptor complexes that phosphorylates the type 1 receptor and activates 
a downstream signaling cascade. The signaling mechanism leads to the transcription of 
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genes which help in cell growth, differentiation, proliferation and apoptosis. One of the 
key role of the TGFβ molecule is to regulate inflammatory processes in the gut [30]. It also 
plays important role in immune system, infectious diseases and cancer [31, 32]. SMADs 
are a family of proteins that are the main signal transducers for the TGFβ superfamily 
receptors. Receptor-regulated Smads (R-Smads), common partner Smads (Co-Smads) and 
inhibitory Smads (I-Smads) are the three sub-types of Smads [33, 34]. The receptor 
regulated Smads comprise of Smads 1-3, Smad 5 and Smad 8/9 [35] which act as the signal 
transducers for the TGFβ receptor [36]. Smad 4 is the only known Co-Smad that are 
primarily localized in the cytoplasm and can co-localize with R-Smads to translocate to the 
nucleus following TGFβ receptor activation [37].  
The third chapter of this thesis studies about the mechanistic pathway in which 
lactate induces the activation of NOX2 and subsequent generation of reactive oxygen 
species, that in turn activates the TGFβ fibrotic pathway in the small intestine under the 
conditions of NAFLD. NLRP3 inflammasomes are formed by the assembly of NLRP3, 
ASC2 and Caspase-1. Once the complex is activated, the Caspase-1 can lead to the 
transformation of the active IL-1β and active IL-18 from their respective latent forms, and 
thereby activating the downstream signaling effects. My fourth chapter studies a novel 
pathway in which the activated NLRP3 inflammsome due to the microcystin exposure 
leads to the over production of IL-18 and IL-1β, that leads to tissue inflammation via 
elevated levels of IL-22 and IL-17A, thereby further promoting tumorigenesis. Thus, the 
entire research mainly focuses on the Non-alcoholic fatty liver disease related gastro-
intestinal inflammation and fibrosis, following exposure from the environmental toxin 
microcystin in a mice model. 
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CHAPTER 2 
ENVIRONMENTAL MICROCYSTIN TARGETS THE MICROBIOME 
AND INCREASES THE RISK OF INTESTINAL INFLAMMATORY 
PATHOLOGY VIA NOX2 IN UNDERLYING MURINE MODEL OF 
NONALCOHOLIC FATTY LIVER DISEASE 
 
 
 
 
 
 
 
 
 
 
- Sutapa Sarkar, Diana Kimono, Muayad Albadrani, Ratanesh K Seth, Philip 
Busbee, Hasan Alghetaa, Dwayne E. Porter, Geoff I. Scott, Bryan Brooks, Mitzi 
Nagarkatti, Prakash Nagarkatti, Chatterjee S. Environmental microcystin targets the 
microbiome and increases the risk of intestinal inflammatory pathology via nox2 in 
underlying murine model of nonalcoholic fatty liver disease.Scientific Reports. 2019 Jun 
19; 9 (1):8742. 
Reprinted here with the permission of the publisher. 
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Abstract: 
With increased climate change pressures likely to influence harmful algal blooms, 
exposure to microcystin, a known hepatotoxin and a byproduct of cyanobacterial blooms 
can be a risk factor for NAFLD associated comorbidities. Using both in vivo and in vitro 
experiments we show that microcystin exposure inNAFLD mice cause rapid alteration of 
gut microbiome, rise in bacterial genus known for mediating gut inflammation and lactate 
production. Changes in the microbiome were strongly associated with inflammatory 
pathology in the intestine, gut leaching, tight junction protein alterations and increased 
oxidative tyrosyl radicals. Increased lactate producing bacteria from the altered 
microbiome was associated with increased NOX-2, anNADPH oxidase isoform. 
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Activationof NOX2 caused inflammasome activation as shown by NLRP3/ASCII and 
NLRP3/Casp-1 colocalizations in these cells while use of mice lacking a crucial NOX2 
component attenuated inflammatory pathology and redox changes. Mechanistically, NOX2 
mediated peroxynitrite species were primary to inflammasome activation and release of 
inflammatory mediators. Thus, in conclusion, microcystin exposure inNAFLD could 
significantly alter intestinal pathology especially by the effects on microbiome and 
resultant redox status thus advancing our understanding of the co-existence of NAFLD-
linked inflammatory bowel disease phenotypes in the clinic. 
 
2.1 INTRODUCTION 
The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing 
proportionately [38]. Fatty liver disease is defined as a benign and non-phenotypic (micro 
vesicular and macro vesicular) accumulation of fat in the liver which often remains 
asymptomatic for years and assumesa role of a silent killer since it takes years to develop 
into a potentially full blown disease [39, 40].Following a second hit or as is proclaimed in 
recent years, multiple hits can progress from a condition of fatty liver (NAFLD) to a more 
progressive inflammatory condition called non-alcoholic steatohepatitis (NASH)[41, 42]. 
NASH is a potentially progressive liver disease that can lead to cirrhosis, hepatocellular 
carcinoma, liver transplantation, and death. NAFLD and subsequent NASH is also 
associated with extrahepatic manifestations such as chronic kidney disease, cardiovascular 
disease and sleep apnoea [43]. Interestingly patients with type 2 diabetes or inflammatory 
bowel disease (IBD) can also have parallel NAFLD-like conditions [44]. NAFLD and its 
9 
more progressive inflammatory form NASH have similar comorbidities in the intestine or 
can result incolon polyps [45]. 
NASH is often diagnosed by abnormal liver chemistry, imaging studies and liver 
biopsy. As there are risks of potential complications during liver biopsy, many patients do 
not opt for liver biopsy [46]. The above fact makes it more likely to become a silent killer 
since there are no early biomarkers for this disease. The mechanisms that account for 
disease progression in NASH are still poorly understood. NAFLD and NASH carry a large 
public health burden and create poor health-related quality of life. An important recent 
study analyzed the 2010 Nationwide Inpatient Sample to compare outcomes and 
associations between patients with nonalcoholic fatty liver disease (NAFLD) [47]. 
Compared with other liver diseases, NAFLD and its inflammatory condition, NASH are 
associated with diverticular, inflammatory bowel, gallstone, and benign pancreatitis 
disorders when these latter disorders are considered as either the principal or associated 
diagnoses on discharge. These associations suggest shared mechanisms of pathology 
between NAFLD/NASH and these benign gastrointestinal disorders [47]. Recent data also 
highlighted the co-existence of NAFLD/NASH and inflammatory bowel disease; both of 
which are increasingly prevalent disorders with significant complications and impact on 
future health burden [48]. In both scenarios the missing links to both NAFLD severity 
inferred by NASH and intestinal inflammatory co-morbidities remain unclear. The 
diagnosis and treatment of the pathology associated with NAFLD/NASH and its 
comorbidities are complicated by the contribution of environmental and genetic factors to 
the risk of developing a progressive course of disease [43]. Thus, it is important to note 
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that a diseased intestine (or an inflamed one) either in an underlying NAFLD or other 
chronic liver disease phenotypes can complicate diagnosis and worsen outcome. 
In the last decade, a growing body of evidence including reports from our 
laboratory has emerged, shedding light on the potential impact of environmental pollutants 
on liver health and, in particular, on NAFLD occurrence and its translation into more 
progressive form NASH [49, 50]. These contaminants have a great steatogenic and 
inflammatory potential and need to be considered as tangible NAFLD risk factors [51]. 
Environmental agents, including endocrine-disrupting chemicals (EDCs), which have been 
linked to other diseases like obesity, may play a role in NAFLD development and 
progression in to NASH [52]. Drinking water disinfectants and poly chlorobiphenyls have 
been also linked to progressive forms of NAFLD more often referred to as toxicity 
associated steatohepatitis or TAH [49]. Recent studies on environmental pollution detail a 
more discrete threat to public health arising from the large scale harmful algal blooms and 
the components associated with it. HABs contain cyanobacterial toxins and their secondary 
metabolites which have been found to have huge toxic potential to human health. 
Microcystins are secondary metabolites produced by cyanobacteria that act as hepatotoxins 
in higher organisms [53]. Harmful, bloom-forming cyanobacteria (CyanoHABs) are 
occurring with increasing regularity in freshwater and marine ecosystems. The most 
commonly occurring cyanobacterial toxins are the hepatotoxic microcystin and nodularin 
[54]. Studies also show that their occurrence is increasing worldwide owing to climate 
change and anthropogenic activities [55].  Further, integrated analysis of proteomic, 
metabolic, histological and cytokine profiles revealed that microcystin significantly 
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inhibited fatty acid β-oxidation and hepatic lipoprotein secretion and promoted hepatic 
inflammation, resulting in NASH [56]. 
Based on the startling evidence of the menace of NAFLD that has assumed 
pandemic proportions, its progression to NASH and comorbidities and the increasing threat 
of environmental pollution from cyanobacterial toxins, we test the hypothesis that chronic 
low dose exposure of microcystin acts as a second hit in the progression of ectopic 
intestinal manifestations of NAFLD/NASH in susceptible populations. In addition, 
microcystin exposure-induced NAFLD severity and ectopic inflammation in the intestine 
arises primarily from its effect on gut microbiome and subsequent inflammatory pathways 
in the intestine. Using a rodent model of NAFLD, the study describes the mechanisms that 
lead to progressive inflammatory condition in the intestine, a mostly asymptomatic and 
under reported consequence in this disease. The results described in this study help advance 
our understanding the underlying pathology in NASH-associated comorbidities. 
 
2.2 MATERIALS AND METHODS 
Materials: Microcystin (MC) was purchased from Cayman Chemical Company 
(Ann Arbor, Michigan). Anti- claudin-2, anti-occludin, anti-HMGB1, anti-F4/80, anti-
NLRP3, anti-caspase1, anti-GP91phox and anti-IL1β primary antibodies were purchased 
from Abcam (Cambridge, MA). Anti-ASC2, anti-p47phox anti-3Nitrotyrosine primary 
antibody was purchased from Santacruz Biotechnology (Dallas, TX). Species-specific 
biotinylated conjugated secondary antibodies and Streptavidin-HRP (Vectastain Elite ABC 
kit) were purchased from Vector Laboratories (Burlingame, CA). Fluorescence-conjugated 
(Alexa Fluor) secondary antibodies, ProLong Gold antifade mounting media with DAPI 
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were purchased from Thermofisher Scientific (Grand Island, NY) and all other chemicals 
which were used in this project purchased from sigma only if otherwise specified. Paraffin-
embedding of tissue sections on slides were done by AML laboratories (Baltimore, MD). 
All other chemicals were of analytical grade and were purchased from Sigma Chemical 
Company. 
 
Mouse model:  Pathogen-free, adult (8 weeks old), male C57BL/6J (WT) mice and 
p47 phox gene deleted (p47phox KO- B6 (Cg)-Ncflm1J/J) mice (Jackson Laboratories, 
Ban Harbor, ME) were used in the study. The groups used for the experiment were the wild 
type mice fed with chow diet only(Lean Control), wild type mice fed with methionine 
choline deficient- high fat diet diet only (NAFLD), wild type mice fed with chow diet and 
then exposed to microcystin(Chow+ MC), wild type mice fed with methionine choline 
deficient diet and then exposed to microcystin(NAFLD+MC), one group of p47 phox KO 
micefed with chow diet and exposed with microcystin(CHOW+MC p47phox KO)and 
another group of p47 phox KO mice fed with methionine choline deficient diet and then 
exposed to microcystin(NAFLD+MC p47phox KO). The total number of animals in each 
group were assessed based on the calculations that ensured enough statistical power of 0.5. 
There were8 mice per group that were allocated to their respective cages following the 
procedure of randomization. A total of 48 mice were used in the experiments for the paper. 
All mice experiments were carried out based on the approval of the institutional animal 
ethics committee (IACUC) at the University of South Carolina (Assurance number: D16-
00028). 
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Diet-induced NAFLD model: Pathogen-free, male, C57BL/6J (WT) and the 
p47phox gene deleted mice (p47 phoxKO) were fed with methionine choline deficient 
(MCD-HFD) diet from 8 weeks to 14weeks for diet-induced NAFLD model until the 
experimental dosing was over and were euthanized soon after. The mice weighed about 25 
grams during the time of euthanizing.All mice had ad libitum access to food and water and 
were housed in a temperature controlled room at 23-24°C with a 12-hour light/dark cycle. 
All animals were treated in strict accordance with the NIH Guide for the Humane Care and 
Use of Laboratory Animals and local IACUC standards. We and others have reported 
previously about the role of NADPH oxidase in the pathology of NASH. NADPH oxidase 
is comprised of several cytoplasmic and membrane subunits which align on the membrane 
for an activated enzyme system. P47 phox is the cytosolic subunit of NADPH oxidase and 
a gene deleted P47 phox mouse was used to ascertain the role of the enzyme in the 
pathology of microcystin-induced progression of intestinal comorbidities inNASH.  
 
Exposure of NAFLD mice to environmental toxin Microcystin: Wild-type 
control and gene specific knockout mice (p47phox KO), fed with MCD-HFD diet for 6 
weeks were thenadministered with microcystin (10µg per kg of mouse, 5 dosages per 
week), through the intraperitoneal route for two weeks.The dosage was giveneach 
afternoon at the same time to eliminate any bias in the study.Since this is a sub-chronic 
study, the cumulative effect of the microcystinon inflammatory phenotypes was 
considered.The mice were euthanized at the completion of dosage and serum and small 
intestine tissue was collected for further processing.  
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Microbiome analysis: 16S rRNA gut microbiota profiling. 16S rRNA gut 
microbial profiling was done on fecal pellets and luminal contents which were collected 
immediately after euthanasia and stored at −80 °C. For 16S rRNA sequencing, genomic 
DNA was extracted from 100 mg of the fecal pellets and luminal contents by using the 
QIAamp DNA Stool Mini Kit (Qiagen, Valencia, CA) according to instructions from the 
manufacturer. DNA libraries were prepared by amplification of the 16S rRNA V3-V4 
hypervariable region with added Illumina adapter overhang nucleotide sequences and 
sequencing with Illumina (San Diego, CA) MiSeq platform. Sequenced reads were than 
analyzed using Nephele (https://nephele.niaid.nih.gov), an open-source analysis tool 
provided by the National Institute of Allergy and Infectious Diseases (NIAID) Office of 
Cyber Infrastructure and Computational Biology (OCICB) in Bethesda, MD [57]. For 
microbial profiling, QIIME FASTQ paired end with chimera removal, open reference, and 
SILVA rRNA database project (Silva_99) options were used.  
 
Intestinal Epithelial cell culture and treatments: Immortalized rat intestinal 
epithelial cell line (IEC-6) was grown and maintained in complete DMEM media 
containing high glucose, Insulin-Transferrin-Selenium (ITS) and 10% FBS at 37°C in a 
humidified atmosphere of 5% CO2. After overnight serum starvation (2.0% FBS) the cells 
were then treated with vehicle (control, C), Rat Leptin (100µg/mL), Microcystin 
(100μg/mL), Apocynin(100µg/ml), 5,5-Dimethyl-1-pyrroline N-oxide [DMPO; 
(100µg/ml)]andphenylboronic acid[FBA;(100µg/ml)], separately or in combinations for 
24 h. The groups for the in-vitro cell treatments were cells only (Control), cells+ rat Leptin 
(Leptin), cells+ rat leptin+ microcystin (Leptin+ MC), cells+ apocynin+ rat leptin+ 
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microcystin (Leptin+ MC+ Apocynin), cells+ phenylboronic acid+ leptin+ microcystin 
(Leptin+ MC+FBA). Upon completion of treatment, cells and supernatant were processed 
for PCR, ELISA and immunofluorescence imaging. All the in-vitro experiments were 
performed three times. 
 
Quantitative Real-Time Polymerase Chain Reaction (qRTPCR): mRNA 
expression in intestinal epithelial cell line was examined by quantitative real-time PCR 
analysis. Total RNA was isolated from the cultured cells and was purified with the use of 
RNeasy mini kit columns (Qiagen, Valencia, CA). cDNA was synthesized from purified 
RNA (1 μg) using iScript cDNA synthesis kit (Bio-rad, Hercules, CA) following the 
manufacturer's standard protocol. Real-time qPCR (qRTPCR) was performed with the 
gene-specific primers using SsoAdvanced SYBR GreenSupermix and CFX96 thermal 
cycler (Bio-rad, Hercules, CA). Threshold Cycle (Ct) values for the selected genes were 
normalized against respective samples internal control (18S). Each reaction was carried out 
in triplicates for each gene and for each sample. The relative fold change was calculated 
by the 2-ΔΔCt method using cells only as a control.  
 
Detection of HMGB1 release (ELISA): Immunoreactivity of HMGB1 was 
detected inthe supernatant of the rat intestinal epithelial cell (IEC-6) groups using Rat High 
Mobility Group Box1 Protein ELISA kit (AbclonalBiotechnology co., Ltd) following 
manufacturer’s protocol.Concentrations of HMGB1 (ng/ml) per well was detected from 
the standard curve. 
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Detection of Systemic Endotoxemia (LAL assay): Serum Endotoxin(EU/ml) was 
detected in the mice groups fed with Chow diet treated with microcystin, NAFLD mice, 
NAFLD mice treated with microcystin and p47phox knockout mice treated with 
microcystin using Pierce LAL Chromogenic Endotoxin Quantitation Kit (Thermo 
Scientific) following manufacturer’s protocol. 
 
Histopathology and Immunohistochemistry (IHC): Formalin-fixed, paraffin-
embedded, 5 µm thick intestine sections were used for histopathology by standard 
hematoxylin and eosin (H&E) staining method and IHC staining. Deparaffinization of the 
sections followed by heat based epitope retrieval and both endogenous peroxidase blocking 
(3% H2O2, 5 min) and serum blocking (5% normal serum, 1h) were carried out. Further, 
sections were incubated with primary antibody (1:500) for 2h at RT and then species-
specific anti-IgG secondary antibodies and conjugation with HRP was performed using 
Vectastain Elite ABC kit following manufacturer’s protocols. Finally, 3, 3-
Diaminobenzidine (DAB) were used as a chromogen substrate and counter stained with 
Mayer’s hematoxylin. Morphometric analysis was done using CellSens Software from 
Olympus America. 
 
Immuno-fluorescence microscopy: The deparaffinized intestine tissue section 
from all the mice groups was subjected to epitope retrieval andpermeabilization (0.01% 
triton X-100) followed by blocking with 5% normal serum. Fixed Rat intestinal epithelial 
cells on the cover glass were subjected to permeabilization (0.01% triton X-100) followed 
by blocking with 10% normal serum. Further, both tissue sections and cells were incubated 
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with primary antibody (1:250) overnight at 4°C. Species-specific anti-IgG secondary 
antibody conjugated with Alexa fluor 633 (red) and Alexa fluor 488 (green) was used to 
observe the antigen-specific immunoreactivity. Sections were mounted inProLong gold 
antifade reagent with DAPI (counter stain). Morphometric analysis was done using 
CellSens Software from Olympus America.  
 
Detection of ATP release: Rat intestinal epithelial cells were treated with the nitric 
oxide (NO) donor (DETA-NONOate) separately and with the combination of DMPO 
(100µg/ml) (DETA-NONOate+DMPO) and phenylboronic acid (FBA; 100µg/ml) 
(DETA-NONOate+ FBA). The supernatants were collected and concentration of ATP 
(µM) per well was detected using Colorimetric ATP Assay kit (from Abcam) following 
manufacturer’s protocol. 
 
Detection of Nitric oxide: Concentration of nitrite (µM) per well  was detected in 
the rat intestinal epithelial cell supernatants treated with Leptin and Microcystinusing 
Griess reagent system kit (Promega, USA) following manufacturer’s protocol. 
 
Statistical Analyses: All in vivo experiments were repeated three times with at 
least eight mice per group (N=8); data from each group of eight mice were pooled). The 
statistical analysis was carried out by unpaired t-test and analysis of variance (ANOVA) 
for assessing difference between multiple groups. For all analysis P<0.05 was considered 
statistically significant. For experiments involving 3 or more groups, data were evaluated 
using one-way ANOVA with multiple comparison post hoc analysis. Data are expressed 
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as mean ± SEM, or as absolute number or percentage for categorical variables. The 
significance level was set at α = 5% for all comparisons. 
 
2.3 RESULTS 
 Pathophysiology of non-alcoholic fatty liver disease in mice liver following 
microcystin exposure. Microcystin is known to primarily affect the liver, being a potential 
hepatotoxin. To study the effects of microcystin in the liver, we fed the mice with MCD-
HFD diet to induce the condition of NAFLD, and then exposed them with microcystin 
(NAFLD+MC). There was high deposition of fat droplets in the NAFLD liver tissue 
compared to the lean control mouse. The liver tissue from the NAFLD+MC showed 
increased inflammation, with infiltration of leukocytes when compared to the chow diet 
fed mice exposed with Microcystin (Fig.2A i-iv). CD68 is known to be the marker for 
activated Kupffer cells during liver inflammation. To determine whether microcystin had 
a role in activating the Kupffer cells in the liver, the immunoreactivities of Kupffer cells 
were analyzed in liver tissue slices (Fig.2B i-iv; 2C). The results showed a significant 
increase in CD68 immunoreactivity in the CHOW+MC group compared to the lean control 
mice (*p<0.05), and simultaneously a significant increase in NAFLD+MC mice compared 
to the NAFLD only group (*p<0.05). 
 
Microcystin exposure in underlying NAFLD worsens gut microbiome changes. 
NAFLD is accompanied by altered gut microbiota with increases in phylum abundance of 
Firmicutes and a subsequent decrease in Bacteriodetes [58]. Similar trends are also 
observed in NAFLD associated inflammatory bowel disease [59]. To study the effects of 
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chronic low dose microcystin exposure in NAFLD, metagenomic analysis of fecal pellets 
in mice were analyzed. Results showed that NAFLD+MC group had an increase in the 
phylum Firmicutes compared to the NAFLD only group, and a significant increase in 
proteobacteria (p<0.01) followed by a marked decrease in the phylum Bacteroidetes when 
compared to NAFLD only group (Fig 3A). Similar trends of a significant increase were 
observed in the phylum abundance of Firmicutes and proteobacteria of the Chow+MC 
group, compared to the Lean Control (LC) group (Fig. 3A). There was a significant 
decrease in the phylum abundance of Verrucomicrobia in the Chow+MC group compared 
to the Lean Control (p<0.01). No significant changes were observed in the phylum 
abundance of Verrucomicrobia in the NAFLD+MC group, when compared to the NAFLD 
only group (Fig. 3A). The order Clostridiales showed a significant increase in abundance 
in the NAFLD+MC group when compared to NAFLD only group while there was a 
significant decrease in the abundance of Bacteriodales in the NAFLD+MC group when 
compared to NAFLD only group (P<0.01) (Fig. 3B). The order abundance of Clostridiales 
also showed a significant increase in the Chow+MC group, compared to the Lean control 
(LC) group.Verrucomicrobiales showed a significant decrease in the Chow+MC group 
compared to the Lean Control (LC) group (Fig 3B). Analysis of the abundance of family 
showed a significant increase in Clostridiaceae inNAFLD+MC groups when compared to 
NAFLD only group (p<0.01) followed by increase inLachnospiraceae, an observation 
consistent with both IBD and NAFLD (Fig. 3C). Similar trends of the significant increase 
in the family of Clostridiaceae and Lachnospiraceae (p<0.01) in Chow+MC group 
compared to the lean control (LC) group were also observed (Fig. 3C). At the genus level, 
abundance of Bacteriodes decreased significantly in the NAFLD+MC group when 
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compared to NAFLD only group (p<0.01) while Blautia and Intestinibacter abundance 
increased significantly in the NAFLD+MC group when compared to NAFLD only group 
(p<0.05)(Fig. 3D).Increase in the Intestinibacter genus abundance was observed in the 
Chow+MC group, compared to the Lean Control (LC) group (Fig 3D).Lactobacillus and 
Enterococcus genus that are widely known as lactate producing bacteria increased 
significantly inNAFLD+MC group when compared to NAFLD only group (p<0.05)(Fig. 
3E and 3F)[60]. The data is consistent with human NAFLD and intestinal comorbidities 
severity since the increased level of the genus Intestinibacter, the family Lachnospiraceae, 
the genus Escherichia, Shigella, and the family Enterobacteriaceae may be a primary 
contributor to NAFLD progression [61]. 
 
Microcystin exposure and resultant worsening dysbiosis in NAFLD is 
positively associated with altered intestinal pathology. Intestinal pathology in 
inflammatory bowel disease assumes a marked signature of epithelial cell loss, disruption 
of villous structures, crypt abscess and granulation [62]. To study the effect of microcystin 
exposure and the resultant worsened dysbiosis inNAFLD, a detailed histopathological 
examination was carried out. Results showed that NAFLD+MC had highly disrupted villi 
structure, increased granulation in the crypt cells, crypt cell abscess, erosion of epithelial 
cells and disrupted lumen when compared to lean control, Chow+MC group and NAFLD 
only group respectively (Fig. 4A(i-iv); Fig. 4B). NAFLD+MC group showed non-parallel 
crypts, variable crypt diameters, bifurcation and branched crypts, consistent with 
significantly higher inflammation scores. Infiltrating leukocytes were fairly common in the 
disruptive villi and in the crypts of NAFLD+MC group when compared to lean, Chow+MC 
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and NAFLD groups respectively. The results suggested that microcystin exposure in 
NAFLD that had consistent dysbiosis were positively associated with moderate to severe 
inflammatory phenotype in the intestines. 
 
Microcystin exposure and resultant worsening dysbiosis in NAFLD is 
positively associated with increased levels of infiltrating leukocytes and NLRP3 
inflammasome activation. Intestinal inflammation in moderate to severe pathology 
associated with inflammatory bowel disease phenotypes show consistent infiltration of 
leukocytes and NLRP3-inflammasome activation [63]. To study the above-mentioned 
effects and their association with microcystin exposure, immunohistochemistry of stained 
slides were analyzed for pan macrophage marker F4/80. Results showed that NAFLD+MC 
group had significantly increased F4/80 immunoreactivity when compared to lean control, 
Chow+MC and NAFLD only groups (Fig. 5A and Fig. 5B)(P<0.01). The extent of staining 
for F4/80 and localizations were shown by a higher magnification image (Fig. 5Av). 
NLRP3 inflammasome activation is a significant event in intestinal inflammation and is 
often associated with downstream IL1β release and pyroptosis[64]. To show the effect of 
microcystin exposure on NLRP3 inflammasome activation, immunoreactivities were 
analyzed for NLRP3 and ASCII. Interestingly, activation of the inflammasome is marked 
by their colocalization thus forming a protein complex [64]. Results showed that 
colocalization events of NLRP3 and ASCII increased significantly inNAFLD+MC group 
when compared to lean, Chow+MC and NAFLD groups (Fig. 6A (i-iv)and Fig. 6B). A 
representative higher magnification image showing the increased colocalizations of 
NLRP3 and ASC II is shown in Fig. 6A-v. The above results showed that the observations 
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were consistent with the histopathology of the affected intestines shown in Fig. 4. 
Interestingly the colocalizations were highly visible in the crypts that had increased 
granulation and abscess. 
 
Microcystin exposure in NAFLD is positively associated with alteration of 
tight junction protein levels and gut leaching leading to systemic low level 
endotoxemia. We and others have shown previously that alteration of gut dysbiosis leads 
to gut leaching and systemic endotoxemia[65, 66]. The studies are also consistent with 
NAFLD and IBD where similar results are reported. To show that microcystin exposure in 
an underlying NAFLD could alter tight junction proteins claudin-2 and occluding, mice 
intestinal tissue slices were analyzed for immunoreactivities of the above-mentioned 
proteins. Results showed that the levels of claudin-2 were significantly increased 
inNAFLD+MC group when compared to lean control, Chow+MC and NAFLD groups 
(Fig. 7A i-iv and  7C(P<0.05)). Occludin levels were significantly decreased in the 
NAFLD+MC group when compared to lean control, Chow+MC and NAFLD groups 
(P<0.05)(Fig. 7B v-viii) and Fig. 7D. Interestingly, microcystin exposure to lean control 
mice also increased claudin-2 levels significantly suggesting MC exposure can lead to 
altered tight junction proteins independently however the conditioned is worsened in an 
underlying NAFLD. We and others have shown that microbial dysbiosis leads to gut 
leaching and low systemic endotoxemia, a condition very much associated with intestinal 
inflammation [66]. Results showed that there was a marked increase in systemic endotoxin 
levels in NAFLD+MC group when compared to Chow+MC and NAFLD groups (Fig 7E) 
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suggesting the dysbiosis, inflammatory phenotypes and altered tight junction proteins 
inNAFLD+MC groups were strongly associated with systemic endotoxemia. 
 
Microcystin exposure in an underlying NAFLD exacerbated oxidative stress, 
radical formation and was associated with increased activation of NADPH Oxidase 2 
(NOX-2). Oxidative stress is central to environmental exposure of toxins following their 
secondary metabolism and affects tissue behavior [50, 67, 68]. Interestingly we have shown 
before that microbiome changes can cause oxidative stress though the exact mechanism 
remained unclear [66]. Based on the strong results of an inflammatory pathology in the 
intestine, we chose to study the mechanisms of oxidative stress following microcystin 
induced dysbiosis in an underlying NAFLD intestinal tissue. Results showed that there was 
a significant increase inNOX-2 membrane assembly and activation as shown by the 
colocalization of the GP91 phox and P47 phox in the intestine when compared to lean 
control, Chow+MC and NAFLD groups (p<0.05)(Fig. 8A i-iv) and 8C. Tyrosine radical 
formation and subsequent tyrosine nitration, a marker of oxidative stress was significantly 
elevated in the NAFLD+MC group when compared to lean control, Chow+MC and 
NAFLD group respectively (P<0.05)(Fig. 8B v-viii; 8D)[69]. The results suggested that 
microcystin exposure and gut dysbiosis correlated well with increased oxidative stress 
primarily through intestinal NOX-2 activation and tyrosine nitration.  
 
NOX2 phenotype is downstream of associated dysbiosis and causes 
inflammasome activation and proinflammatory IL1b release typical of the NLRP3-
ASC-2 axis. To study the role of NOX-2 in the inflammatory changes in the NAFLD 
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intestine following microcystin exposure we used mice that have the genetic deletion of 
the cytosolic component of NOX-2 (henceforth referred to as P47 phox knockout mice). 
The p47 phox KO group was treated identically as the CHOW+MC and the NAFLD+MC 
groups. Results showed that CHOW+MC (P47 phox KO) ) and NAFLD+MC (P47 phox 
KO) mice showed a significant decrease in colocalization of NLRP3/ASC II when 
compared to CHOW+MC and NAFLD+MC groups respectively (Fig. 9Ai-iv and 9C). 
Inflammasome activation is also dependent on the binding of Caspase 1with NLRP3 to 
form a stable inflammasome complex [70]. NLRP3 and Caspase-1 colocalization events 
were significantly decreased in the P47 phox KO group when compared to CHOW+MC 
and NAFLD+MC groups suggesting a decreased NLRP3 inflammasome activation 
(p<0.05)(Fig. 9B v-viii and 9D). Inflammasome activation is followed by a release of IL-
1β for the pathway to proceed downstream [63]. IL1β protein levels as measured by 
immunohistochemistry decreased significantly in the p47 phox KO group when compared 
to CHOW+MC and NAFLD+MC groups suggesting that NOX-2 was required for the 
inflammasome activation and IL1β release in the diseased intestine (Fig. 10Ai-iv and 
10B)(P<0.05). Interestingly, the IL1β was localized in the same region as the NOX-2 
suggesting the histopathological sites of the events are likely the same.  
 
NOX2 is essential for alteration of gut adhesion via regulating the protein 
levels of tight junctions, release of HMGB1 and serum endotoxemia. Results showed 
that use of P47 phox knockout mice for both the CHOW+MC and NAFLD+MC groups 
showed a significant decrease in Claudin-2 protein levels when compared to CHOW+MC 
and NAFLD+MC groups respectively (P<0.05)(Fig. 11Ai-iv and 11C). The levels of 
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another tight junction protein occludin increased significantly in the CHOW+MC (P47 
phox KO) group when compared to CHOW+MC group, and also there was a significant 
increase in NAFLD+MC (P47 phox KO) group when compared to NAFLD+MC group 
suggesting that NOX2 was important for the alterations of these proteins crucial for 
maintaining gut barrier integrity (p<0.05)(Fig. 11B v-viii and 11D). P47phox KO mice also 
had decreased protein levels of HMGB1 (Fig. 12A i -iv; 12 B), a damaged associated 
molecular protein known to cause inflammatory pathology downstream of NLRP3 
inflammasome activation when compared to Chow+MC  and NAFLD+MC groups 
respectively (P<0.05). Serum endotoxin levels also showed a decreased trend in p47 phox 
KO group when compared to CHOW+MC and NAFLD+MC groups (Fig. 12C). A 
representative higher magnification image of NAFLD+MC group suggests that higher 
HMGB1 was primarily localized in the crypt cells that showed a parallel cell damage and 
leukocyte infiltration (Fig 12Ai-iv). 
 
Microcystin exposure in intestinal epithelial cells causes the generation of 
peroxynitrite species following NOX-2 activation in the presence of nitric oxide and 
causes inflammatory phenotype. We and others have shown that NOX2 activation inthe 
intestine in an underlying NAFLD is followed by peroxynitrite generation, which 
subsequently acts to target various cellular signaling processes leading to inflammation 
[69]. In this study we modelled a cellular system where leptin was used to mimic a cellular 
NAFLD microenvironment since the disease is accompanied by leptin resistance [71]. This 
is also supported by the fact that leptin is proinflammatory and usually acts via 
peroxynitrite to target inflammation [69]. Results showed that microcystin exposure 
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significantly increased NLRP3 inflammasome activation when compared to cell only 
controls (only leptin controls showed similar result) while incubation with peroxynitrite 
scavenger phenyl boronic acid (FBA) or NOX2 inhibitor apocynin significantly decreased 
the activation (Fig. 13A i-iv and 13B)(P<0.05). Release of HMGB1 was also decreased 
significantly in the FBA and Apocynin groups when compared to Lep+MC group (Fig. 
13C) suggesting that NOX2 mediated peroxynitrite generation is crucial for NLRP3-
inflammasome activation and DAMP release in these cells. Monocyte chemoattractant 
protein-1 (MCP-1) is responsible for infiltration of leukocytes at the site of tissue injury 
[72]. MCP-1 levels were significantly decreased in the epithelial cells treated with both 
apocynin and FBA suggesting that leukocyte infiltration was also influenced by NOX-2 
mediated peroxynitrite generation (Fig. 14A)(P<0.05).  
 
Nitric oxide is crucial for NOX2-induced peroxynitrite generation and NLRP3 
inflammasome activation. Peroxynitrite generation requires a diffusion-controlled 
reaction of nitric oxide and superoxide released from NOX-2 or a subsequent enzyme 
capable of releasing the same [73]. We also showed increased nitric oxide release in cells 
that were incubated with leptin +microcystin. The NO release was significantly higher 
inthe leptin+Microcystin group when compared with either cells only group or cells 
incubated with leptin alone (P<0.05) (Fig. 14 B). To show that nitric oxide is crucial for 
the mechanisms of peroxynitrite generation and NLRP3 inflammasome activation we used 
a NO donor DETANONOATE [74]. Since extracellular ATP is one of the prime ligands 
for inflammasome activation, we studied the release of ATP from the intestinal epithelial 
cells following microcystin exposure in the presence of NO donor, NOX-2 inhibitor 
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apocynin and peroxynitrite scavenger FBA. Results showed that extracellular ATP release 
was significantly increased in the presence of the NO donor and was consistent with our 
previous data that show leptin primed cells incubated with microcystin released NO 
(P<0.05)(Fig. 15A). FBA or oxyradical scavenger and nitrone spin trap DMPO 
significantly decreased ATP levels, when compared to NO donor treatment group (P<0.05) 
(Fig. 15A).  
 
DETANONOATE, the NO donor significantly increased inflammasome 
activation (NLRP3-ASCII colocalization, Fig. 15B i-iii and 15D) and recruitment of 
Caspase-1 in the inflammasome complex (Fig. 15C iv-vi and 15E)(p<0.05) while the 
administration of FBA, a peroxynitrite scavenger significantly decreased the NLRP3 
activation and Caspase-1 recruitment suggesting NOX2-derived superoxide and nitric 
oxide in the cellular microenvironment caused peroxynitrite generation and NLRP3 
activation. 
 
2.4 DISCUSSION 
We report a novel mechanism of environmental low dose microcystin exposure-
induced exacerbation of intestinal inflammatory pathology in an underlying NAFLD. 
Microcystinexposure independently altered and worsened gut dysbiosis at the phylum, 
order, family and genus levels. Though the altered dysbiosis bore the signature of worsened 
NAFLD, new information related to significant increases in the order Clostridiales, family 
clostridiaceae and genus blautia were observed. Interestingly, microcystin alone only 
increased the abundance of these bacteria marginally suggesting that an underlying 
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asymptomatic NAFLD helped exacerbate the effect of microcystin on the digestive tract. 
It is important to note that increases in the abundance of Clostridiales, Clostridiaceae, 
Lachnospiraceae and Intestinibacter has been indicative of severe intestinal disturbances 
inhumans [75, 76]. Increased abundance of Clostridiaceae has been associated with 
increased incidences of IBD-RA (Rheumatoid Arthritis) [77]. Our finding of increased 
abundance of Clostridiales, Lachnospiraceae and the genus Intestinibacter are recognized 
as strong biomarkers of early onset of Chron’s disease, an intestinal inflammatory 
condition with no discrete therapeutic regimen [78]. The result reported in our study where 
mice with asymptomatic NAFLD were exposed to microcystin provides a strong basis that 
environmental exposure in patients with NAFLD carry an immense risk of progressing to 
a more severe phenotype of the disease. Importantly as mentioned before, NAFLD is now 
considered as a pandemic and is rapidly being reported not only in the developed world but 
encompasses more populations in the developing countries of India and China [79]. As 
more and more water bodies across the world report existence of harmful algal blooms and 
increased cyanobacterial abundance, it is not difficult to predict that our findings lay a 
strong basis for defining the risk factors in susceptible population’s worldwide especially 
intestinal comorbidities of an existing disease [80]. These exacerbations can be difficult to 
treat and will affect health care costs tremendously. Our results, though show a strong 
association of microbial changes with microcystin exposure does not rule out its role as a 
hepatotoxic agent [81]. However, our data strongly suggest that microcystin exposure in 
low doses can influence the microbiome in parallel to its toxic effects on the liver.  
Our results show that a change in gut microbiome following microcystin exposure 
was associated strongly with intestinal epithelium erosion, crypt abscess and granulated 
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cells, hallmarks of intestinal inflammatory disease. The results assume significance since 
NAFLD severity is often associated with inflammatory bowel disease, where the cause and 
pathology remained unclear [44, 47]. On the contrary, many reports show that IBD and 
NAFLD severity coexist and bear the same pathological signatures that we show in our 
model study suggesting that environmental microcystin exposure can be a possible cause 
to trigger disease severity and coexistence. Mechanistically we also report the activation 
of NLRP3-inflammasome and loss of gut barrier integrity, a prime pathological event in 
many inflammatory disease conditions that involve the intestine [63]. Gut barrier integrity 
is also crucial for prevention of leaching of intestinal damage associated molecular patterns 
capable of eliciting low lying inflammation in various organ systems including the liver 
[82]. Our results of increased claudin-2 and parallel decreases inOccludin followed by 
increased endotoxin in the circulation indicate a strong possibility of gut leaching following 
microcystin exposure and microbial dysbiosis. The results also provide a strong rationale 
for the role of NLRP3 inflammasome as a mechanism for the downstream inflammatory 
events following microcystin-associated dysbiosis inNAFLD.  
Several reports tie microbial dysbiosis to inflammatory events in the gut but the 
pathways connecting these two significant events remain obscure. We have shown 
previously that inflammasome activation or the pathways leading to proinflammatory 
disease conditions in the intestine with or without NAFLD might implicate the role of 
redox signaling where NADPH oxidase (NOX-2) plays an important role[66, 82]. 
Strikingly, the dysbiosis that preceded inflammasome formation was also associated 
strongly with a significant increase inNOX-2 activation and tyrosine radical formation in 
our model. We found that the lactate producing bacteria in the gut (Lactobacillus and 
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Enterococcus) showed a >2 fold increase in Microcystin exposure. Strikingly, lactate 
produced in drosophila is known to activate NOX-2[83]. The study by Latsenko et al 
showed that a null mutation in Drosophila PGRP-SD was associated with overgrowth of 
Lactobacillus plantarum in the fly gut and a shortened lifespan and L. plantarum-derived 
lactic acid triggered the activation of the intestinal NADPH oxidase [83]. Though no such 
study has been reported in disease models, we justifiably assume that increases in lactate 
producing bacteria (Lactobacillus and Enterococcus) following microcystin exposure 
might trigger the increased lactate needed to activate NOX-2. The result is very likely 
correlative at this point but a measurement of intestinal lactatemight put an end to this 
speculation and remains a minor limitation in the present study.  
The involvement of NOX-2-derived reactive oxygen species in inflammatory 
phenotype was also proven by the use of NOX-2-knockout mice that had a deletion of the 
p47 phox gene. NOX-2 knockout mice showed decreased inflammation, NLRP3 activation 
and decreased gut leaching, thus confirming its role in microbial derived intestinal tissue 
injury. The result also confirmed that NOX-2 interfered with inflammation downstream of 
microbial dysbiosis since p47 phox knockout mice did not show the pattern of microbial 
changes akin to what is reported following microcystin exposure. We have shown 
previously that NOX-2 mediates the redox signaling process in inflammation via the 
generation of peroxynitrite[67]. Notably, peroxynitrite species are formed following a 
diffusion-controlled reaction with superoxide (likely derived from NOX-2 and nitric 
oxide[48]. We identified that NOX-2 activation following microcystin exposure and gut 
dysbiosis led to peroxynitite generation, an observation confirmed further with the use of 
specific peroxynitite scavenger phenyl boronic acid (FBA)[84]. 
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Possible bias and limitations of the study. There is scant evidence of microcystin 
exposure from cyanobacterial blooms and how it affects disease development. Our animal 
model mimics a hypothetical scenario where environmental microcystin exposure to 
populations having existing NAFLD. Though clinically, it is an arduous task to 
differentiate the environmental effect in the progression of NAFLD, our study attempts to 
explain the pathophysiology of such a scenario where increased harmful algal blooms or 
exposure to microcystin can increase the risk of NAFLD progression to NASH. 
Microcystin exposure in our study was based on a cumulative sub-chronic model with only 
two weeks. This particular dose, used in our study was far from adequate in predicting the 
different types and nature of exposures that humans might receive. A recent study Greer B 
et al describe a porcine model of microcystin exposure which might be a good model to 
pursue for detection of pathology in organ systems{Greer, 2018 #2632}[85]. Future studies 
with diverse exposure regiment needs to be done to assess the severity of disease 
progression. Studies in rodent models of NASH have been paramount to the elucidation of 
the pathophysiology and drug discovery to understand and treat humanNASH knowing 
fully well that the disease is presented late and there are no clinical biomarkers of this 
disease. Thus, it is justifiable to assume that our present study will help in advancing our 
knowledge in understanding the environmental effects inNASH progression. Further, it is 
known that mice and humans share significant similarities in anatomy and physiology. A 
recent study also compares the details of the mice and human microbiota {Nguyen, 2015 
#2631} [86]. The study also finds that there are atleast 79 genera occurring in both human 
and mouse gut microbiotas. The relative abundances of most of the dominant genera in 
mouse and human are quite different. Also, Clostridium, Bacteroides and Blautia, on the 
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contrary, have a similar relative abundance in both organisms though lactobacillus seemed 
to be very abundant only in the murine species. Despite this, the major gut microbiota shifts 
that have been observed in different obesity, NAFLD and colitis mouse models are similar 
to those found in human IBD studies. 
Thus, in summary, our studies show a novel pathway of microcystin-induced 
exacerbation of NAFLD comorbidities via gut dysbiosis and redox signaling. The study 
also supports an emerging hypothesis that chronic microcystin exposure as might happen 
through drinking water contaminated with cyanobacterial toxins might aid in disease 
complexity and pathogenesis. The present study also can be used as a model for 
microcystin risk assessment in cohorts who are already plagued with asymptomatic and 
silent disease conditions like NAFLD and/or chronic conditions like obesity, Type 2 
Diabetes and hypertension. Though the present study is conducted in a preclinicalset up, 
future studies need to be conducted in human cohorts that associate exposure of 
cyanobacterial toxins and disease conditions with parallel insights to changes in gut 
microbiome. 
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Figure 2.1 Pathology of microcystin exposure in liver. Formalin-fixed, paraffin-
embedded 5μm liver slices from lean mouse control (N=8), wild type mouse control 
(NAFLD) (N=8), wild type mouse group exposed with Microcystin (CHOW+MC) (N=8) 
and another NAFLD group of mice exposed with Microcystin (NAFLD+MC) (N=8) were 
used for hematoxylin and eosin imaging. (A)Representative Hematoxylin and Eosin 
stained(H&E) images (20X) of liver sections showed NAFLD pathophysiology of control 
mice group, wild type NAFLD (WT-NAFLD), control group exposed to microcystin 
(CHOW+MC), and another group of NAFLD mice group exposed to Microcystin.(B) (i-
iv)Representative Immunohistochemistry images (20x) depicting CD68 immuno-
reactivity (C)Morphometric analysis of CD68immunoreactivity (*p < 0.05). 
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Figure 2.2 Fecal pellets and luminal contents were collected from the animals of each group 
after sacrifice and microbial analysis was done for the groups Lean Control (LC) (N=8), 
CHOW+MC(N=8), NAFLD(N=8) and NAFLD+MC(N=8). (A) Microbiome analysis (in 
%OTU) of the phylum Actinobacteria, Firmicutes, Bacteriodetes, Verrucomicrobia, 
Proteobacteria(B) Microbiome analysis (in %OTU) of the order Bacteriodales, 
Clostridiales,Verrucomicrobiales, Lactobacillales, Erysipelotrichales(C) Microbiome 
analysis of the family (in %OTU)Bacteriodaceae, Clostridaceae, Lachnospiraceae, 
Ruminococcaceae, Peptostreptococcaceae(D) Microbiome analysis of the genus (in 
%OTU)Bacteriodes, Blautia, Lachnoclostridium, Intestinibacter, Ruminiclostridium(E-F) 
Comparison of the lactate producing bacteria from the between Lactobacillus and 
Enterococcus among the Lean Control, CHOW+MC,NAFLD and NAFLD+MC groups. 
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Figure 2.3 Formalin-fixed, paraffin-embedded 5μm intestinal slices from lean mouse 
control (N=8), wild type mouse control (NAFLD) (N=8), wild type mouse group exposed 
with Microcystin (CHOW+MC) (N=8) and another NAFLD group of mice exposed with 
Microcystin (NAFLD+MC) (N=8) were used for hematoxylin and eosin imaging. 
Representative Hematoxylin and Eosin stained(H&E) images (20X) of intestinal sections 
showed NAFLD pathophysiology of control mice group, wild type NAFLD (WT-
NAFLD), control group exposed to microcystin (CHOW+MC), and another group of 
NAFLD mice group exposed to Microcystin. (B)Pathological ScoresinNAFLD associated 
damage onMicrocystin exposure. The pathological scores were assigned arbitrarily 
according to the extent of damage, disruption in the lumen and granulation in crypt cells 
caused in the small intestine.  
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Figure 2.4 Formalin-fixed, paraffin-embedded 5µmintestinal slices from lean mouse control 
(No. of mice per group, N=8), wild type mouse control (NAFLD) (N=8), wild type mouse 
group exposed with Microcystin (CHOW+MC) (N=8) and another NAFLD group of mice 
exposed with Microcystin (NAFLD+MC) (N=8)were used for immunohistochemistry 
imaging.  (A)(i-iv)Representative Immunohistochemistry images (20x) and (v) higher 
magnification image (60X) of NAFLD+MC group depicting F4/80 
immunoreactivity(B)Morphometric analysis of F4/80 immunoreactivity (*p < 0.05). 
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Figure 2.5 Formalin-fixed, paraffin-embedded 5µmintestinal slices from lean mouse control 
(No. of mice per group, N=8), wild type mouse control (NAFLD) (N=8), wild type mouse 
group exposed with Microcystin (CHOW+MC) (N=8) and another NAFLD group of mice 
exposed with Microcystin (NAFLD+MC) (N=8)were used for immunofluorescence 
imaging. (A)(i-iv) Immunofluorescence images in 20X depicting NLRP3 (red) and ASC2 
(green) colocalization, counterstained with DAPI (blue) in LC, CHOW+MC, NAFLD and 
NAFLD+MC group of mice intestine. (v) A higher magnificationimagewas taken at 60 X 
magnification for the NAFLD+MC group. (B) Morphometric analysis of NLRP3-ASC2 
colocalization immunoreactivity. Y-axis shows % positive immunoreactive area (% ROI) 
(n=5, analysis from five separate microscopic fields) (*p < 0.05) 
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Figure 2.6 Formalin-fixed, paraffin-embedded 5μmintestinal slices from lean mouse control 
(No. of mice per group, N=8), wild type mouse control (NAFLD) (N=8), wild type mouse 
group exposed with Microcystin (CHOW+MC) (N=8) and another NAFLD group of mice 
exposed with Microcystin (NAFLD+MC) (N=8)were used for immunofluorescence 
imaging. (A)Immunofluorescence images depicting Claudin-2 (red) (i-iv) and (B)Occludin 
(red) (v-viii), counterstained with DAPI (blue) in LC, CHOW+MC, NAFLD and 
NAFLD+MC group of mice intestine. Imageswere taken at 20X magnification.(C) 
Morphometric analysis of Claudin-2 immunoreactivity. Y-axis shows % positive 
immunoreactive area (% ROI) (n=5, analysis from five separate microscopic fields) (*p < 
0.05)(D) Morphometric analysis of Occludinimmunoreactivity. Y-axis shows % positive 
immunoreactive area (% ROI) (n=5, analysis from five separate microscopic fields) 
(0.01<*p<0.05). (E)Systemic endotoxemia wasmeasured by Chromogenic LAL assay in 
serum of LC, CHOW+MC, NAFLD and NAFLD+MC group of mice.
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Figure 2.7 Formalin-fixed, paraffin-embedded 5µm intestinal slices from lean mouse 
control (No. of mice per group, N=8), wild type mouse control (NAFLD) (N=8), wild type 
mouse group exposed with Microcystin (CHOW+MC) (N=8) and another NAFLD group 
of mice exposed with Microcystin (NAFLD+MC) (N=8)were used for 
immunofluorescence imaging. (A)(i-iv) Immunofluorescence images depicting gp91 phox 
(red) and p47 phox (green) colocalization, counterstainedwith DAPI (blue) in LC, 
CHOW+MC, NAFLD and NAFLD+MC group of mice intestine. Imageswere taken at 20X 
magnification. (B)(v-viii)  Immunofluorescence images depicting 3-Nitrotyrosine (red), 
counterstained with DAPI (blue) in LC, CHOW+MC, NAFLD and NAFLD+MC group of 
mice intestine. Imageswere taken at 20X magnification.(C) Morphometric analysis of gp91 
phox-p47phox colocalized immunoreactivity. Y-axis shows % positive immunoreactive 
area (% ROI) (n=5, analysis from five separate microscopic fields) (0.01<*p < 0.05).(D) 
Morphometric analysis of 3-Nitrotyrosine immunoreactivity. Y-axis shows % positive 
immunoreactive area (% ROI) (n=5, analysis from five separate microscopic fields) (*p < 
0.05). 
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Figure 2.8 Formalin-fixed, paraffin-embedded 5μmintestinal slices from wild type mouse 
group exposed with Microcystin (CHOW+MC) (No. of mice per group, N=8), 
CHOW+MC group with P47 phox gene knock out (P47phox KO) (N=8), NAFLD wild 
type group of mice exposed with Microcystin (NAFLD+MC) (N=8) and another 
NAFLD+MC group with P47 phox gene knock out (P47phox KO) (N=8) were used for 
immunofluorescence and immunohistochemistry imaging. (A)(i-iv) Immunofluorescence 
images depicting NLRP3 (red) and ASC2 (green) colocalization, counterstainedwith DAPI 
(blue) in CHOW+MC, CHOW+MC(P47phoxKO), NAFLD+MC, NAFLD+MC(P47phox 
KO) group of mice intestine. Imageswere taken at 20X magnification.(B)(v-viii) 
Immunofluorescence images depicting NLRP3 (red) and Caspase-1 (green) 
colocalization,counterstained with DAPI (blue) in CHOW+MC,CHOW+MC 
(P47phoxKO),NAFLD+MC, NAFLD+MC(P47phox KO) group of mice intestine. Images 
were taken at 20X magnification.(C) Morphometric analysis of NLRP3-ASC2 colocalized 
immunoreactivity. Y-axis shows % positive immunoreactive area (% ROI) (n=5, analysis 
from five separate microscopic fields) (*p < 0.05). (D) Morphometric analysis of NLRP3-
Caspase-1 colocalized immunoreactivity. Y-axis shows % positive immunoreactive area 
(% ROI) (n=5, analysis from five separate microscopic fields) (0.01 < *p < 0.05). 
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Figure 2.9 Formalin-fixed, paraffin-embedded 5µm intestinal slices from wild type mouse 
group exposed with Microcystin (CHOW+MC) (No. of mice per group, N=8), 
CHOW+MC group with P47 phox gene knock out (P47phox KO) (N=8), NAFLD group 
of mice exposed with Microcystin (NAFLD+MC) (N=8)and another NAFLD +MC group 
with P47 phox gene knock out (P47phox KO) (N=3)were used for immunohistochemistry 
imaging.(A)(i-iv) Immunohistochemistry images depicting IL-1β immunoreactivity in 
CHOW+MC, CHOW+MC (P47phox KO), NAFLD+MC, NAFLD+MC(P47phox KO) 
group of mice intestine. Imageswere taken at 20X magnification.(B)Morphometric 
analysis of IL-1βimmunoreactivity. Y-axis shows % positive immunoreactive area (% 
ROI) analysis from n=5, five separate microscopic fields) (*p <0.05). 
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Figure 2.10 Formalin-fixed, paraffin-embedded 5 μmintestinal slices from wild type mouse 
group exposed with Microcystin (CHOW+MC) (No. of mice per group, N=8), 
CHOW+MC group with P47 phox gene knock out (P47phox KO) (N=8), NAFLD wild 
type group of mice exposed with Microcystin (NAFLD+MC) (N=8) and another NAFLD 
+MC group with P47 phox gene knock out (P47phox KO) (N=8) were used for 
immunofluorescence and immunohistochemistry imaging. (A)(i-iv) Immunofluorescence 
images depicting Claudin-2 (red) , counterstainedwith DAPI (blue) in 
CHOW+MC,CHOW+MC (P47phox KO),NAFLD+MC, NAFLD+MC(P47phox KO) 
group of mice intestine. Imageswere taken at 20X magnification.(B)(v-
viii)Immunofluorescence images depicting Occludin (red),counterstained with DAPI 
(blue) in CHOW+MC, CHOW+MC (P47phox KO), NAFLD+MC, NAFLD+MC(P47phox 
KO) group of mice intestine. Images were taken at 20X magnification.(C) Morphometric 
analysis of Claudin-2 immunoreactivity. Y-axis shows % positive immunoreactive area (% 
ROI) (n=5, analysis from five separate microscopic fields) (*p < 0.05). (D) Morphometric 
analysis of Occludinimmunoreactivity. Y-axis shows % positive immunoreactivearea (% 
ROI) (n=5, analysis from five separate microscopic fields) (0.01 <*p <0.05). 
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Figure 2.11 Formalin-fixed, paraffin-embedded 5 μmintestinal slices from wild type mouse 
group exposed with Microcystin (CHOW+MC) (No. of mice per group, N=8), 
CHOW+MC group with P47 phox gene knock out (P47phox KO) (N=8), NAFLD wild 
type group of mice exposed with Microcystin (NAFLD+MC) (N=8) and another NAFLD 
+MC group with P47 phox gene knock out (P47phox KO) (N=8) were used for 
immunohistochemistry imaging.(A)(i-iv)Immunohistochemistry images depicting 
HMGB1 immunoreactivity in CHOW+MC, CHOW+MC (P47phox KO), NAFLD+MC, 
NAFLD+MC (P47phox KO) group of mice intestine. Imageswere taken at 20X 
magnificationand (v) higher magnification image (60X) of NAFLD+MC group depicting 
HMGB1 immunoreactivity.(B)Morphometric analysis of HMGB1 immunoreactivity. Y-
axis shows % positive immunoreactive area (% ROI) (n=5, analysis from five separate 
microscopic fields). (C)Systemic endotoxemia was measured by Chromogenic LAL assay 
in serum of CHOW+MC, CHOW+MC (P47phox KO), NAFLD+MC and NAFLD+MC 
(P47phox KO) group of mice (*p < 0.05). 
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Figure 2.12 Intestinal epithelial (IEC-6) cell line was used as control (CONTROL), NAFLD 
was induced with leptin in another group which was exposed to Microcystin 
(LEPTIN+MC), and another group of cells exposed to leptin and microcystin was blocked 
by Apocynin and FBA (LEPTIN+MC+APOCYNIN) (LEPTIN+MC+FBA). The cell 
groups were used forimmunofluorescence imaging. (A)(i-iv) Immunofluorescence images 
depicting NLRP3 (red) and ASC2(green) colocalization, counterstainedwith DAPI (blue) 
in CONTROL, LEPTIN+MC, LEPTIN+MC+APOCYNIN, LEPTIN+MC+FBA group of 
IEC-6 cells. Images were taken at 40X magnification.(B) Morphometric analysis of 
NLRP3-ASC2 colocalized immunoreactivity. Y-axis shows % positive immunoreactive 
area (% ROI) (n=5, analysis from five separate microscopic fields) (0.01 < *p < 
0.05).(C)HMGB1 adducts were measured by ELISA in IEC-6 cell supernatant of 
CONTROL, LEPTIN+MC, LEPTIN+MC+APOCYNIN, LEPTIN+MC+FBA groups 
(0.01 < *p < 0.05).  
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Figure 2.13 mRNA expression of MCP-1 in CONTROL, LEPTIN+MC, 
LEPTIN+MC+APOCYNIN, LEPTIN+MC+FBA group of IEC-6 cells was performed 
using qRTPCR. mRNA expression is represented as fold change of NAFLD on Y-axis 
(0.01< *p < 0.05). (B)Nitric oxide release was detected by the Griess Reagent system using 
Intestinal Epithelial cells (IEC-6) cell supernatants for the groups CONTROL, LEPTIN, 
LEPTIN+ MC, to study the concentration of nitrite formed per well. (n=3, analysis from 
three samples) (*p < 0.05). 
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Figure 2.14 ATP assay was performed using the Intestinal Epithelial cells (IEC-6) cell 
supernatants for the groups Control, DETA-NONOate treated, DETA-NONOate treated+ 
FBA and DETA-NONOate treated + DMPO, to study the concentration of ATP per well. 
(n=3, analysis from three samples) (*p < 0.05).Intestinal epithelial (IEC-6) cell line was 
used as control (CONTROL), one group was treated with the supernatant of IEC-6 cell line 
that was treated with NO-donor (DETA-NONOate), another group of cells were blocked 
by FBA and then was treated with the NO-donor (DETA-NONOate) (DETA-
NONOate+FBA). The cell groups were used for immunofluorescence imaging. (B)(i-iii) 
Immunofluorescence images depicting NLRP3 (red)-ASC2(green) colocalization and 
(C)(iv-vi) NLRP3 (red)- Caspase-1(green) colocalization, counterstainedwith DAPI (blue) 
in CONTROL, DETA-NONOate ,DETA-NONOate+FBA, group of IEC-6 cells. 
Imageswere taken at 20X magnification.(D) Morphometric analysis of NLRP3-ASC2 and 
(E)NLRP3-Caspase1 colocalized events. Y-axis shows % positive immunoreactive area 
(% ROI) (n=5, analysis from five separate microscopic fields) (*p < 0.05). 
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CHAPTER 3 
 
HIGHER INTESTINAL AND CIRCULATORY 
LACTATE ASSOCIATED NOX2 ACTIVATION LEADS 
TO AN ECTOPIC FIBROTIC PATHOLOGY IN 
MURINE FATTY LIVER DISEASE 
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Abstract: 
Intestinal fibrosis is a common complication of Inflammatory Bowel Disease (IBD) 
and in Crohn's Disease globally, though it may remain subclinical without any intestinal 
obstruction. Studies also reveal that chronic inflammation such as NAFLD increases the 
risk of intestinal fibrosis in the affected regions of the gut. We have recently shown that 
PP2A inhibition in underlying NAFLD led to altered gut microbiome, increased abundance 
of lactate producing bacteria and intestinal inflammation. This led us to further investigate 
the effects of the PP2A inhibitor in activating the TGF-β fibrotic pathway in the intestines 
that might be mediated by redox enzyme NOX2 via increased lactate. Exposure to PP2A 
inhibitor and higher serum lactate was associated with NOX2 activation in vivo that led to 
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increased SMAD2/3-SMAD4 colocalization and high alpha smooth muscle actin (α-SMA) 
immunoreactivity in the intestines. Mechanistically, immortalized rat intestinal epithelial 
cells treated with lactate and PP2Ainh separately led to higher NOX2 activation, 
phosphorylation of TGFβR1 receptor and subsequent SMAD 2/3-4 colocalization 
inhibitable by apocynin (NOX2 inhibitor), FBA, a peroxyntirite scavenger and DMPO, a 
nitrone spin trap, catalase (hydrogen peroxide decomposer) and superoxide dismutase. 
Inhibition of NOX2-induced redox signaling also showed significant decrease in collagen 
protein thus suggesting a strong redox signaling induced activation of an ectopic fibrotic 
manifestation in the intestines. Hence, this study provides mechanistic insights into a role 
of a protein phosphatase inhibitor on lactate production, lactate-induced NOX2 activation 
and a NOX2 mediated exacerbation of the cell differentiation and fibrosis in the intestines 
in underlying inflammatory pathology of the liver. 
 
 
3.1 INTRODUCTION 
 
Nonalcoholic fatty liver disease (NAFLD) is a condition of excess accumulation of 
fat (steatosis) in the liver cells [1]. It is considered as a global pandemic that affects 70% 
of the obese population of the United States, according to the Centre for Disease Control 
and Prevention. Several studies suggest that almost 28–31% of the general population have 
steatosis and 8% have a raised alanine transaminase (ALT) due to NAFLD [2, 3]. Although 
90% of the individuals suffering from NAFLD have the condition of steatosis in the liver 
without any cases of mortality [4-6], often the steatosis is accompanied with excessive 
scarring and inflammation, leading to the condition of Nonalcoholic steatohepatitis 
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(NASH). NAFLD, if remains untreated, often progresses to NASH in which there is 
increased inflammation, fibrosis that may lead to cirrhosis and hepatocellular carcinoma 
[7, 8]. Studies suggest that people suffering from obesity, type 2 diabetes and insulin 
resistance are more prone to develop NAFLD, which becomes a major public health threat 
due to the unavailability of clinical symptoms. 
People suffering from NAFLD, can be subjected to certain risk factors including 
chronic inflammation, stress and injury, leading to Inflammatory Bowel Disease (IBD) 
[48], though the pathogenesis of NAFLD in IBD patients remains unclear. Studies suggest 
that inflammatory bowel disease is also becoming an increasingly prevalent disorder in 
North America. Under these conditions, it becomes a major concern to study the intestinal 
fibrosis which is known to be a common complication of the Inflammatory Bowel Disease, 
according to research [87, 88]. Che-yung Chao et al. reported that there has been several 
data that supports the co-morbidities of NAFLD and Inflammatory Bowel Disease [48]. 
Our previous studies have shown that there has been a close association of NAFLD with 
colonic inflammation and inflammatory bowel disease [82]. Progression of NAFLD can 
also be potentiated by several factors including environmental toxins. There has been 
several reports of harmful algal blooms in the fresh and brackish waters which can release 
certain toxins that possess a serious threat to the individuals [89]. Microcystin (MC-LR) is 
the toxin produced by freshwater cyanobacteria (also known as blue-green algae) called 
Microcystis. Microcystins are highly toxic with relatively low doses required for lethal 
effects [90]. Microcystin (MC-LR) being a potential hepatotoxin primarily affects the liver 
but it is also known to also affect other mammalian organs like heart, kidney, intestines 
and tissues [91].  
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Intestinal microbiome plays an important role in maintaining the gut homeostasis 
[92]. Several studies have reported that microcystin alters the gut microbiome in mice [93] 
and leads to the accumulation of microcystin in the small intestinal villi regions [94]. 
Increased apoptosis, loss of epithelial cells and intraepithelial lymphocyte decrease were 
also observed in the murine small intestine according to several research studies [94-96]. 
In our recently published research work, we observed that there was an alteration in the 
taxonomy of the gut microbes, with a phylum abundance of Firmicutes, Proteobacteria in 
the microcystin treated groups and subsequently a decrease in the phylum abundance of 
Bacteroidetes, compared to the control groups. Similar trends were observed in different 
microbes in the order, class, family and genus levels. An abundance in the lactate producing 
bacteria was also observed due to exposure to the microcystin. It led us to believe that 
Microcystin exposure may possibly cause adverse effects to the small intestine. Once it is 
exposed, microcystin is taken up by the intestinal epithelia and disrupts the cellular 
functions by deactivating and inhibiting different enzymes. Studies reported that 
microcystin specifically inhibited protein phosphatase 1 (PP1) and protein phosphatase 2A 
(PP2A)[18, 26, 97], leading to tumorigenic phenotype. Microcystin interacts with the 
catalytic subunit of the PP2A enzyme and leads to the uncontrolled inhibition of the protein 
phosphatases [98]. The interaction follows a two-step mechanism, in which the catalytic 
subunit of the enzyme is first inactivated and then it forms covalent bonds between its side 
chain and amino acid residues [18, 99]. This disrupts the activity of the PP2A enzyme 
which is known to be a potent tumor suppressor [99]. The PP2A enzyme plays an important 
role in regulating the transforming growth factor β fibrotic pathway [100]. Being a 
phosphatase, it dephosphorylates and thereby deactivates the activin like kinase-5 
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(ALK5/TGF-β receptor 1)[101], to stall the downstream signaling pathway. In this 
scenario, microcystin forms covalent bonds with the protein phosphatase, thus allowing the 
kinases to phosphorylate and activate TGF-βR1 for the onset of the TGF-β pathway leading 
to fibrosis. These effects of the PP2A inhibitor (microcystin) are exacerbated if there is an 
underlying chronic inflammatory condition like non-alcoholic fatty liver disease.  
In this context, it becomes increasingly important to study the role of the PP2A 
inhibitor microcystin in inducing pathogenesis in the gut in the underlying conditions of 
NAFLD. This current study investigates the role of the PP2A inhibitor microcystin in 
altering the gut microbiome and the also onset of the fibrotic pathway in the murine 
intestines under an inflammatory phenotype. We hypothesized that microcystin lead to the 
increase in several pathogens and lactate producing bacteria, which increased the serum 
lactate levels in the PP2A inhibitor treated mice under the conditions of NAFLD, as 
compared to the control mice. Over-production of lactate leads to the activation of NOX-2 
and the release of reactive oxygen species (preferably peroxynitrite) which activates TGF-
β. The enzyme PP2A is known to dephosphorylate the TGF-βR1 receptor and inhibit the 
progression of downstream SMAD pathway leading to fibrosis. Microcystin, known to be 
a PP2A inhibitor, specifically binds to the catalytic subunit of PP2A, thereby deactivating 
the enzymatic action of PP2A. This leads to the receptor activation of TGF-βR1 by its 
phosphorylation, which activates the downstream SMAD2/3- SMAD4 pathway leading to 
a fibrotic pathology in the intestine. The study uses a murine model of NAFLD and in vitro 
studies with rat immortalized intestinal epithelial cells to elucidate the mechanisms. 
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3.2 MATERIALS AND METHODS 
 
Materials: Specific PP2A inhibitor (Microcystin, MC) was purchased from 
Cayman Chemical Company (Ann Arbor, Michigan) and leptin was purchased from 
BioVision (Milpitas, CA). Anti-TGF-β, anti-collagen I, anti-alpha smooth muscle actin, 
anti-fibronectin, anti-3Nitrotyrosine and anti-GP91phox primary antibodies were 
purchased from Abcam (Cambridge, MA). Anti-Smad2/3, anti-Smad 4, anti-vimentin, 
anti- TGF-βR1 and anti-p47phox primary antibody was purchased from Santa Cruz 
Biotechnology (Dallas, TX). Anti-phospho TGF-βR1, primary antibody was purchased 
from Thermofisher Scientific (Waltham, MA). Apocynin, phenyl boronic acid (FBA), 
DMPO, Catalase and superoxide dismutase was purchased from Sigma Aldrich. Wild-type 
and gene-specific knockout (KO) mice including P47 phox knock out mice were purchased 
from The Jackson Laboratories (Bar Harbor, ME). Animal diets were purchased from 
Research Diets (New Brunswick, NJ). Species-specific biotinylated conjugated secondary 
antibodies and Streptavidin-HRP (Vectastain Elite ABC kit) were purchased from Vector 
Laboratories (Burlingame, CA). Fluorescence-conjugated (Alexa Fluor) secondary 
antibodies, ProLong Gold antifade mounting media with DAPI were purchased from 
Thermofisher Scientific (Grand Island, NY) and all other chemicals which were used in 
this project purchased from sigma only if otherwise specified. Paraffin-embedding of tissue 
sections on slides were done by AML laboratories (Baltimore, MD). All other chemicals 
were of analytical grade and were purchased from Sigma Chemical Company. 
 
Mouse model:  Pathogen-free, adult (8 weeks old), male C57BL/6J (WT) mice and 
p47 phox gene deleted (p47phox KO- B6 (Cg)-Ncflm1J/J) mice (Jackson Laboratories, Ban 
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Harbor, ME) were used in the study. The groups used for the experiment were the wild 
type mice fed with chow diet only(Lean Control), wild type mice fed with methionine 
choline deficient- high fat diet only (NAFLD), wild type mice fed with chow diet and then 
exposed to the PP2A inhibitor(Chow+ PP2Ainh.), wild type mice fed with methionine 
choline deficient diet and then exposed to PP2A inhibitor(NAFLD+ PP2Ainh.), and 
another group of p47 phox KO mice fed with methionine choline deficient diet and then 
exposed to PP2A inhibitor (NAFLD+PP2Ainh.p47phox KO). The total number of animals 
in each group were assessed based on the calculations that ensured enough statistical power 
of 0.5. There were 6 mice per group that were allocated to their respective cages following 
the procedure of randomization. A total of 30 mice were used in the experiments for the 
paper. All mice experiments were carried out based on the approval of the institutional 
animal ethics committee (IACUC) at the University of South Carolina (Assurance number: 
D16-00028). 
 
Diet-induced NAFLD model: Pathogen-free, male, C57BL/6J (WT) and the 
p47phox gene deleted mice (p47 phoxKO) were fed with methionine choline deficient 
(MCD-HFD) diet (Research diets, New Brunswich, NJ) from 8 weeks to 14weeks for diet-
induced NAFLD model until the experimental dosing was over and were euthanized soon 
after. The mice weighed about 25 grams during the time of euthanizing. All mice had ad 
libitum access to food and water and were housed in a temperature controlled room at 23-
24°C with a 12-hour light/dark cycle. All animals were treated in strict accordance with 
the NIH Guide for the Humane Care and Use of Laboratory Animals and local IACUC 
standards.  
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Exposure of NAFLD mice to environmental toxin Microcystin: Wild-type 
control and gene specific knockout mice (p47phox KO), fed with MCD-HFD diet for 6 
weeks were then administered with PP2A inhibitor (10µg per kg of mouse, 5 dosages per 
week), through the intraperitoneal route for two weeks. The dosage was given each 
afternoon at the same time to eliminate any bias in the study. Since this is a sub-chronic 
study, the cumulative effect of the PP2A inhibitor on inflammatory phenotypes was 
considered. The mice were euthanized at the completion of dosage and serum and small 
intestine tissue was collected for further processing. 
 
Intestinal Epithelial cell culture and treatments: Immortalized rat intestinal 
epithelial cell line (IEC-6) was grown and maintained in complete DMEM media 
containing high glucose, Insulin-Transferrin-Selenium (ITS) and 10% FBS at 37°C in a 
humidified atmosphere of 5% CO2. After overnight serum starvation (2.0% FBS) the cells 
were then treated with vehicle (control, C), Rat Leptin (100µg/mL), Lactate (15ng/µL), 
Apocynin(100µg/ml), 5,5-Dimethyl-1-pyrroline N-oxide [DMPO; (100µg/ml)]and 
phenylboronic acid[FBA;(100µg/ml)], Catalase (50µg/ml) and Superoxide dismutase 
(100µg/ml) separately or in combinations for 24 h. The lactate concentration was 
determined from the serum lactate of mice samples. The groups for the in-vitro cell 
treatments were cells only (CONTROL), cells+ rat Leptin (LEPTIN), cells+ lactate 
(LACTATE), cells+ rat leptin+ lactate (LEPTIN+LACTATE) cells+ apocynin+ rat leptin+ 
lactate (LEPTIN+ LACTATE+ APO), cells+ phenylboronic acid+ leptin+ microcystin 
(LEPTIN+ LACTATE+ FBA), cells+ DMPO+ rat leptin+ lactate (LEPTIN+ LACTATE+ 
DMPO), cells+ catalase+ rat leptin+ lactate (LEPTIN+ LACTATE+ CATALASE), cells+ 
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superoxide dismutase+ rat leptin+ lactate (LEPTIN+ LACTATE+ SOD). Upon completion 
of treatment, cells and supernatant were processed for PCR, western blot and 
immunofluorescence imaging. All the in-vitro experiments were performed three times.  
Another group of cells were treated with the PP2A inhibitor (microcystin) to determine its 
effects on the downstream pathway. The groups used for the experiment were cells only 
(CONTROL), cells+ rat Leptin (LEPTIN), cells+ + rat leptin+ PP2Ainh (LEP+PP2Ainh), 
cells+ PP2Ainh (PP2A inh Only), cells+ apocynin+ rat leptin+ PP2Ainh (LEP+ PP2Ainh+ 
APO), cells+ phenylboronic acid+ leptin+ PP2Ainh (LEP+ PP2Ainh + FBA), cells+ 
DMPO+ rat leptin+ PP2Ainh (LEP+ PP2Ainh + DMPO), cells+ catalase+ rat leptin+ 
PP2Ainh (LEP+ PP2Ainh + CATALASE), cells+ superoxide dismutase+ rat leptin+ 
PP2Ainh (LEP+ PP2Ainh + SOD). The treatment was done for 24 hours and upon 
completion of treatment, cells and supernatant were processed for immunofluorescence 
imaging. All the in-vitro experiments were performed three times.  
 
Picrosirius Red Staining: Sections of small intestine tissue from each mouse were 
collected and fixed in 10% neutral buffered formalin. These formalin-fixed, paraffin 
embedded tissues were cut in 5 μm thick sections. Picrosirius red staining of formalin-
fixed, paraffin embedded small intestine tissue was done using a Nova ultra-sirius red stain 
kit following manufacturer's instructions (IHC-World). Liver sections were observed under 
a 10X objective of a light microscope. Morphometric analysis of the stained regions of the 
tissue sections was performed using cellSens software (Olympus). The small intestine 
fibrosis was defined, for a small intestine section, as the ratio of the area of stained collagen 
fibers versus the total area of small intestine section, expressed in percent. 
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Immunohistochemistry: The small intestine sections were deparaffinized using a 
standard protocol. Briefly, sections were incubated with xylene twice for 3 min, washed 
with xylene: ethanol (1:1) for 3 min, and rehydrated through a series of ethanol (twice with 
100%, 95%, 70%, 50%), twice with distilled water, and finally rinsed twice with PBS 
(Sigma-Aldrich). Antigen epitope retrieval of the deparaffinized sections was performed 
using epitope retrieval solution and steamer (IHC-World, Woodstock, MD) for 45 minutes. 
3%H202 was used for 15 minutes to block the endogenous peroxidases. The primary 
antibody for α-SMA (Abcam, Cambridge, MA) and vimentin (Santa Cruz Biotechnology, 
Dallas, TX) were used overnight in recommended dilutions. Species specific biotinylated 
conjugated secondary antibody and streptavidin conjugated with HRP were used to 
perform antigen-specific immunohistochemistry according to manufacturer’s standard 
protocols. 3, 3’ Diaminobenzidine (Sigma-Aldrich, St.Louis, MA) was used as a 
chromogenic substrate. Tissue sections were counter-stained with Mayer’s hematoxylin 
(Sigma-Aldrich). Phosphate buffer saline was used for washing three times between the 
steps. Sections were finally mounted in Aqua mount (Fisher Scientific) and observed under 
a 20X objective using an Olympus BX43 microscope (Olympus, America). Morphometric 
analysis was done using CellSens Software from Olympus America (Center Valley, PA). 
 
Immuno-fluorescence staining and microscopy: In vivo, formalin-fixed, 
paraffin-embedded small intestine tissue sections were subjected to deparaffinization 
according to standard instructions. Epitope retrieval of the deparaffinized sections was 
done with an epitope retrieval solution and steamer (IHC World) according to the 
manufacturer's protocol. The primary antibodies anti-gp-91phox, anti-p47phox, anti-
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smad2/3, anti-smad4, anti-TGF-β, anti 3-nitrotyrosine, anti- fibronectin, and anti-phospho 
TGF-βR1, were used at recommended dilutions. Species-specific anti-IgG secondary 
antibodies conjugated with Alexa Fluor 488 (Invitrogen) were used. The sections were 
mounted in a ProLong Gold antifade reagent with DAPI (Life Technologies, Carlsbad, 
CA). Images were taken under 20X, 40X and 60X magnification with an Olympus BX43 
microscope.In vitro, after completion of the treatments under serum-starved conditions as 
in cell culture, cells attached on coverslips were fixed with 10% neutral buffered saline. 
After the cells were washed with PBS containing 0.1% Triton X (Sigma), they were 
blocked with 3% BSA, 0.2% Tween (Fisher), 10% FBS in PBS. Cells were incubated with 
primary antibodies anti- α-SMA, anti-gp-91phox, anti-p47phox, anti-smad2/3, anti-smad4, 
anti 3-nitrotyrosine, anti-phospho TGF-β and anti-3NT followed by species-specific Alexa 
Fluor 633 and 488. The stained cells attached on the coverslips were mounted on slides 
with ProLong Gold antifade reagent with DAPI (Life Technologies) and viewed under 40X 
and 60X magnification with an Olympus BX43 microscope. 
 
Western Blot Analysis: SDS PAGE-Resolved protein bands were transferred to 
nitrocellulose membrane using precut nitrocellulose/filter paper sandwiches (Bio-Rad 
Laboratories, Hercules, CA) and Trans-Blot Turbo transfer system (Bio-Rad) in case of 
low molecular weight proteins and using wet transfer module from Invitrogen for high 
molecular weight proteins. Primary antibodies (Abcam) were used at recommended 
dilutions, and compatible horseradish peroxidase-conjugated secondary antibodies were 
used. Pierce ECL Western Blotting substrate (Thermo Fisher Scientific, Rockford, IL) was 
used for detection. The blot was imaged using G: BoxChemi XX6 (Syngene imaging 
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systems) and subjected to densitometry analysis using Image J. Primary antibodies 
phosphor-TGF-βR1 (ThermoFisher Scientific) total TGF-βR1 and β-actin (Santa Cruz 
Biotechnology), were used at recommended dilutions (1:1000), and 
compatible horseradish peroxidase-conjugated secondary antibodies at (1:5000) dilutions 
were used. 
 
Lactate Assay: Serum lactate was measured in the blood serum of the murine 
models using the Lactate Assay kit from Sigma Aldrich using manufacturer’s protocol. 
Serum was collected from the samples of lean mouse control (LC), chow diet fed mice 
treated with PP2A inhibitor (Chow+ PP2Ainh), high fat diet fed mice (NAFLD), high fat 
diet fed mice treated with PP2A inhibitor (NAFLD+ PP2Ainh) and P47 phox knockout 
mice fed with high fat diet and treated with PP2A inhibitor. The experiment was repeated 
thrice with triplicates of each sample.  
 
Proximity Ligation Assay: The small intestine sections were deparaffinized using 
a standard protocol used in immunofluorescence and immunohistochemistry procedures. 
Epitope retrieval of the deparaffinized sections was done with an epitope retrieval solution 
and steamer (IHC World) according to the manufacturer's protocol. The tissues were then 
blocked for 60 minutes at 37˚C by DuoLink blocking solution (Sigma Aldrich). The 
primary antibodies are then diluted (1:250) using the provided DuoLink antibody diluent 
(Sigma Aldrich) and incubated overnight at 4˚C. The tissues were then washed using Wash 
Buffer A (Sigma Aldrich) as recommended and are incubated for 60 minutes at 37˚C with 
the PLA PLUS and MINUS probes (1:5 dilution) (Sigma Aldrich), according to the 
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manufacturer’s protocol. After subsequent washes, the Ligase is diluted (1:40) in DuoLink 
Ligation Buffer (Sigma Aldrich) and incubated for 30 minutes at 37˚C. The polymerase 
diluted (1:80) in the DuoLink Amplification Buffer (Sigma Aldrich) is added to the tissues 
and incubated for 100 minutes at 37˚C. The tissues are then washed with Wash Buffer B 
according to manufacturer’s protocol, and mounted with ProLong Gold antifade reagent 
DAPI (Life Technologies, Carlsbad, CA). The tissues were viewed under 40X 
magnification with an Olympus BX43 microscope. 
 
Statistical Analyses: All in vivo experiments were repeated three times with at 
least eight mice per group (N=8); data from each group of eight mice were pooled). The 
statistical analysis was carried out by unpaired t-test and analysis of variance (ANOVA) 
for assessing difference between multiple groups. For all analysis P<0.05 was considered 
statistically significant. For experiments involving 2 groups where distribution of data was 
not clearly parametric, Mann-Whitney U tests were performed with GraphPad Prism 
Software Inc, CA, and Version 5.03. For experiments involving 3 or more groups, data 
were evaluated using one-way ANOVA with multiple comparison post hoc analysis. Data 
are expressed as mean ± SEM, or as absolute number or percentage for categorical 
variables. The significance level was set at α = 5% for all comparisons. 
 
3.3 RESULTS 
 
Pathology of the murine small intestine following specific inhibition of PP2A 
under the conditions of NAFLD. Specific inhibition of PP2A leads to a fibrotic pathology 
in the murine small intestine. To study the role of Microcystin-LR (MC), the PP2A 
 
 
61 
 
inhibitor, we used mice fed with MCD-HFD to induce NAFLD, followed by a low dose of 
Microcystin (NAFLD+PP2Ainh). Another group of mice fed with Chow diet and exposed 
to Microcystin were also used (CHOW+PP2Ainh). Small intestine tissues were analyzed 
for fibrosis by Picro Sirius red staining. Increased collagen fiber deposition in the 
NAFLD+PP2Ainh group of mice was observed compared to the NAFLD control mice 
(*p<0.05) (Fig. 1A (i-iv), C). A slight increase in the collagen fiber deposition in the lean 
control mice (CHOW+PP2Ainh.) compared to the lean control was also observed (Fig. 1A 
(i-iv), C). Several studies have also revealed that expression of Vimentin is required for 
Epithelial to Mesenchymal transition [102]. It is also known to play an important role in 
the development of fibrosis by stabilizing the collagen mRNA [103]. Our results showed a 
significant increase in the vimentin expression in the NAFLD+PP2Ainh group compared 
to the NAFLD mice control (*p<0.05) (Fig. 1B (i-iv), D). Similar marked increase of 
Vimentin expression was observed in the CHOW+PP2Ainh group compared to the lean 
mouse control (Fig. 1B (i-iv), D), indicating a condition for the development of fibrosis in 
the small intestine. Results showed a marked increase of serum lactate levels were in both 
the CHOW and NAFLD mice exposed to the PP2A inhibitor as compared to either lean 
mice or NAFLD control mice respectively (Fig.1E). The results of marked increase in 
lactate levels were consistent with our recently published study that showed a higher 
abundance of lactate producing bacteria following PP2A inhibition (Sarkar S et al, 2019). 
 
Exposure to PP2A inhibitor alters the redox status of the murine intestine. We 
have previously reported that the alteration of microbiome leads to the activation of the 
NADPH oxidase 2 that leads to increased oxidative stress in the intestine. NOX 2 is 
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activated when the cytosolic P47 Phox subunit of NADPH oxidase associates with its 
membrane counterpart GP91 Phox. We used immunofluorescence staining method to study 
the membrane association of the two subunits in mice small intestine. The results were 
analyzed based on the number of co-localization events (yellow) (Fig 2A (i-iv), C). We 
observed that the NAFLD+PP2A and CHOW+PP2Ainh groups had a significant increase 
in the colocalization events, when compared to the NAFLD only group and the lean mouse 
control respectively (**0.01<p<0.05) (Fig 2A (i-iv), C). A proximity ligation assay was 
performed to confirm the activation of NOX 2 followed by the inhibition of PP2A. The 
proximity ligation assay is a technique that is used to detect protein interactions, 
modifications and specificity [104]. It is used as a confirmative technology extending from 
the conventional co-localization and co-immunoprecipitation techniques. Interactions 
between the GP91 Phox and P47 Phox proteins due to close proximity was shown by red 
spots that was detected by immunofluorescence microscopy. Results showed a significant 
increase in the red spots in NAFLD+PP2A inh group when compared to the NAFLD only 
group (#p<0.01) (Fig 2B (i-iv), D), thereby confirming the activation of NOX 2 on 
exposure to the PP2A inhibitor microcystin. 
 
Activation of NADPH Oxidase 2 regulates the TGF-β receptor activation 
following PP2A inhibitor. TGF-β has been known to play an important role in the 
activation of the Fibrotic pathway [105-108]. To determine the role of NOX 2 in inducing 
the TGF-β expression following microcystin exposure, we used the mice that had the P47 
Phox gene deleted (P47 Phox knockout mice). The mice were treated with the PP2A 
inhibitor microcystin in a similar manner as the CHOW+PP2A inh and NAFLD+PP2A inh 
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groups. Immunofluorescence staining was performed to study the TGF-βactivation 
pathway in the murine intestine, induced by the increased oxidative stress. Results showed 
a marked increase in TGF-β level in NAFLD+PP2A inh group compared to the NAFLD 
only control (Fig 3A (i-iv), C). A significant decrease in TGF-β immunoreactivity was 
observed in the P47 Phox knockout mice (*p<0.05) (Fig 3A (v), C), suggesting the role of 
NOX 2 in the activating the TGF-β signaling pathway. The TGF-β molecule binds to the 
TGF-βRII receptor complex and activates the activin receptor-like kinase 5 (ALK5) by 
phosphorylating the TGF-βRI receptor [101]. We performed immunofluorescence staining 
to detect the phospho-TGF-βR1 immunoreactivity in small intestine tissue. Our results 
showed that there was a significant increase in phospho-TGF-βR1 levels in the 
NAFLD+PP2A inh group as compared to the NAFLD only group (#p<0.01), and also a 
significant increase in the CHOW+PP2A inh group as compared to the lean mouse control 
(*p<0.05) (Fig. 3B (i-iv), D). A significant decrease was observed in the P47 Phox gene 
deleted group of mice compared to the NAFLD+PP2A inh group suggesting a crucial role 
of NOX 2 in activating the downstream TGF-β signaling pathway (*p<0.05) (Fig. 3B(v), 
D). We also performed western blotting technique to measure the phosphorylated TGF-
βR1 protein levels in tissue lysates from the mice groups, in vivo. Similar trends of a 
significant increase in the phospho-TGF-βR1 levels in the CHOW+PP2A inh compared to 
the lean mouse control group (*p<0.05) and significant increase in NAFLD+PP2A inh 
group as compared to the NAFLD only group (*p<0.05) were observed, which was 
significantly decreased in the P47 Phox gene deleted mice group (*p<0.05). We also 
checked the total-TGF-βR1 protein levels and the levels were significantly decreased in 
the CHOW+PP2Ainh and the NAFLD+PP2Ainh, when compared to the lean control and 
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the NAFLD only group respectively (Fig. 3E). The fold change was observed by 
quantifying the protein bands of phospho-TGF-βR1 with respect to the total-TGF-βR1 
(*p<0.05) (Fig. 3F). 
 
NADPH oxidase 2 mediated TGF-βR1 activation regulates the translocation 
of SMAD2/3-SMAD4 assembly in the nucleus. Formation of the SMAD2/3-SMAD4 
complex is crucial for activation of the downstream pathway for TGF-β signaling leading 
to collagen deposition [109]. The activated TGF-βR1 phosphorylates the SMAD2/3[110], 
which then binds with SMAD4 and translocate to the nucleus leading to the TGF-β signal 
transduction [111]. Mouse small intestine tissues were used to study the immunoreactivity 
of SMAD2/3 and SMAD4, and the colocalization events were studied using 
immunofluorescence microscopy. Our results showed that the nuclear colocalization 
events were significantly higher in the NAFLD+ PP2Ainh group compared to the NAFLD 
only group (*p<0.05) (Fig. 4A(i-iv), C), and also a similar significant increase was 
observed in the CHOW+PP2A inh group compared to the lean mouse control (#p<0.01) 
(Fig. 4A(i-iv), C). Proximity ligation assay was used to confirm the SMAD2/3 and SMAD4 
protein interactions in the nucleus due to proximity, and it was visible as red spots when 
detected by immunofluorescence microscopy. Results showed a significant increase in the 
red spots in the NAFLD+PP2A inh group compared to the NAFLD only group (*p<0.05), 
and a marked increase in the CHOW+PP2A inh group compared to the lean mouse control 
group (Fig. 4B(i-iv), D). A significant decrease in the SMAD2/3-SMAD4 colocalization 
(#p<0.01) (Fig 4A(v), C) and a subsequent significant decrease in the red spots (** 0.01< 
p< 0.05) (Fig 4B(v), D) in the P47 Phox gene deleted mice group. 
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TGF-β signal transduction due to nuclear translocation of the SMAD2/3-
SMAD4 assembly cause extracellular matrix protein deposition and fibrosis. 
Fibronectin is a component of the extracellular matrix present in the cell [112-114], which 
is required for collagen matrix assembly and also plays an important role in fibrosis. 
Expression of fibronectin is often considered as an important marker for ECM 
accumulation [115-118]. The expression of alpha smooth muscle actin also denotes the 
presence of myofibroblastic cell phenotype, since it is considered as a marker for collagen 
producing fibroblasts and has been known to play a crucial role in fibrosis [119]. 
Immunohistochemical analysis and immunofluorescence staining was done using mice 
small intestine tissues to detect α-SMA and fibronectin immunoreactivity. Our results 
showed a significant increase in α-SMA immunoreactivity in the NAFLD+PP2A inh group 
compared to the NAFLD only group (#p<0.01) (Fig 5A(i-iv), C), and a marked increase in 
α- SMA immunoreactivity in the CHOW+PP2A inh group compared to the lean mouse 
control group (Fig 5A(i-iv), C). Similar trends of significant increase in Fibronectin 
immunoreactivity in NAFLD+ PP2A inh and CHOW+PP2A inh groups were observed 
compared to the NAFLD only and the lean mouse control groups respectively (*p<0.05) 
(Fig 5B(i-iv), D). Significant decrease in both α-SMA (Fig 5A (v), C) and fibronectin (Fig 
5B (v), D) immunoreactivity was observed in the P47 Phox gene deleted mice group 
compared to the treated group (#p <0.01). 
 
Lactate causes the formation of peroxynitrite radical and increased oxidative 
stress due to NOX 2 activation in intestinal epithelial cells. Alterations of the 
microbiome due to exposure with PP2A inhibitor has led to the release of lactate that can 
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possibly cause the activation of NADPH oxidase 2 and thereby increased oxidative stress 
in the murine intestine, under the conditions of non-alcoholic fatty liver disease. To 
establish this model of study, we treated the intestinal epithelial cells with leptin to create 
the underlying conditions of NAFLD, and then stimulated with lactate, which is believed 
to be in the system due to alteration of the gut microbiome by exposing to the PP2A 
inhibitor microcystin. Results showed that cells that has been primed with leptin and then 
stimulated with lactate showed significantly increased NOX 2 activation when compared 
to the cells only, leptin only and lactate only treated cells (*p<0.05) (Fig 6A(i-iv), B). 
Interestingly, we also observed that lactate alone can lead to the activation of NOX 2 
thereby playing a crucial role in activating the downstream pathways. Activation of NOX 
2 lead to increased oxidative stress through the formation of peroxynitrite radical. To 
estimate peroxynitrite formation, the cells were stained for 3-nitrotyrosine 
immunoreactivity and was analyzed with immunofluorescence microscopy. Results 
suggested a significant increase in the LEPTIN+LACTATE group compared to the cells 
only group (*p<0.05) (Fig 6C (i-iv), D). A significant amount of peroxynitrite production 
was also observed in the lactate only group which denoted that lactate released due to 
altered gut microbiome itself can generate oxidative stress in the murine intestine. 
Incubation with the peroxynitrite scavenger phenyl boronic acid (FBA), NOX2 inhibitor 
apocynin, nitrone spin trap DMPO, hydrogen peroxide inhibitor catalase and the 
superoxide scavenger superoxide dismutase significantly decreased the peroxynitrite 
radical formation (#p<0.01) (Fig 6C(v-ix), D) and the oxidative stress compared to the 
treated group.  
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Increased oxidative stress up-regulates the TGF-β levels leading to nuclear 
translocation of R-SMAD assembly. Activation of NOX 2 and increased oxidative stress 
leads to the expression of TGF-β which thereby binds to the TGF-β receptor II complex 
thereby phosphorylating TGF-βR1. The activated TGF-βR1 further induces the complex 
formation of the SMAD2/3-SMAD4, by phosphorylating SMAD2/3, which then 
translocate to the nucleus. Our results showed a significant increase of phosphorylated 
TGF-βR1 in the group LEPTIN+LACTATE compared to the cells only group (#p<0.01) 
(Fig 7A (i-iv), B). Significant decrease in the expression of phosphorylated TGF-βR1 was 
observed in the groups incubated with apocynin, FBA, DMPO, catalase and SOD 
(#p<0.01) (Fig 7A (v-ix), B). Expression of the phosphorylated TGF-βR1 and total TGF-
βR1 with respect to β-actin was also determined using the technique of western blot using 
the intestinal epithelial cell lysates. We observed that there was a significant increase of 
phosphorylated TGF-βR1 in the LEPTIN+LACTATE group of cell lysates compared to 
the cells only. This increase was found to be significantly decreased in the groups that were 
incubated with the inhibitors apocynin, FBA, DMPO, Catalase and SOD. Significant 
decrease in the total-TGF-βR1 protein levels in cell lysates were observed in the 
LEPTIN+LACTATE group as compared to the lean control (*p<0.05) (Fig 7C). There was 
a significant increase observed in the groups incubated with the inhibitors apocynin, FBA, 
DMPO, Catalase and SOD (*p<0.05) (Fig 7C). The fold change was observed by 
quantifying the protein bands of phospho-TGF-βR1 with respect to the total-TGF-βR1 
(*p<0.05) (Fig 7D). Following the activation of the TGF-βR1, a significant increase in the 
SMAD2/3-SMAD4 colocalization was observed in the groups treated with 
LEPTIN+LACTATE compared to the cells only group (*p<0.05) (Fig 8A (i-iv), B). The 
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colocalization events were significantly decreased in the groups that were incubated with 
the inhibitors apocynin, FBA, DMPO, Catalase and SOD (*p<0.05) (Fig 8A (v-ix), B), 
suggesting the role of the reactive oxygen species in activating the TGF-β downstream 
signaling pathway. 
 
Activation of the TGF-β signaling pathway cause collagen deposition and a 
change of the epithelial to myofibroblastic phenotype of the cells. α- smooth muscle 
actin, a marker for detecting the myofibroblastic cells, was used to stain the intestinal 
epithelial cells. Results showed that there was a significant increase in α-SMA 
immunoreactivity in the LEPTIN+LACTATE group compared to the cells only group 
(*p<0.05) (Fig 9A (i-iv), B). Col 1α immunoreactivity was detected through 
immunofluorescence staining to analyze the expression of collagen which is believed to be 
mark the formation of the fibrotic phenotype. Results suggested a significant increase in 
the collagen levels in the LEPTIN+LACTATE group, as compared to the cells only group 
(#p<0.01) (Fig 10A (i-iv), B). There was a significant decrease in the α-SMA (*p<0.05) 
(Fig 9B (v-ix), B) and Col 1α (Fig 10B (v-ix), B) immunoreactivity when the cells were 
incubated with apocynin (**0.01<p<0.05), FBA (**0.01<p<0.05), DMPO (#p<0.01), 
catalase (#p<0.01) and SOD (#p<0.01), and then treated with leptin and lactate. 
 
Exposure of protein phosphatase 2A inhibitor microcystin to intestinal 
epithelial cells lead to the fibrotic pathology in the murine intestine. Treatment of the 
IEC-6 cells with the microcystin, lead to the activation of NOX-2 and also the release of 
reactive oxygen species, measured by the immunoreactivity of 3-nitrotyrosine. Results 
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showed that there was a significant increase in the NOX-2 in the LEP+PP2Ainh group 
(*p<0.05), compared to the control and the PP2Ainh only groups (Fig 11A (i-iv), B). The 
immunoreactivity was measured by the colocalization events of GP91 Phox and cytosolic 
p47 phox proteins. The results also depicted a significant increase in the 3-nitrotyrosine 
immunoreactivity in the LEP+PP2Ainh group compared to the control and the PP2Ainh 
only group (0.01<**p<0.05) (Fig 11C (i-iv) and D). We observed that the effect of the 
PP2A inhibitor only on the intestinal cells was not as pronounced as when the cells were 
treated with the PP2A inhibitor in presence of leptin, suggesting that there is a higher 
possibility of intestinal fibrotic pathology under inflammatory conditions of NAFLD. The 
peroxynitrite radical formation was significantly decreased when the cells were incubated 
with FBA, apocynin, DMPO, catalase and superoxide dismutase (*p< 0.05) (Fig 11C (v-
ix), D).  
 
Exposure of the cells to microcystin also showed a significant increase of 
phosphorylated TGF-βR1 in the group LEP+PP2Ainh group compared to the control 
and PP2Ainh only group (*p<0.05) (Fig 12A (i-iv), B), which was observed to significantly 
decrease in the groups incubated with apocynin, FBA, DMPO, catalase and SOD (*p<0.05) 
(Fig 12A (v-ix), B). Results also showed a significant increase in the SMAD2/3-SMAD4 
colocalization in the group treated with LEP+PP2Ainh compared to the control and 
PP2Ainh only group (*p<0.05) (Fig 13A (i-iv), B). The colocalization events were 
significantly decreased in the groups incubated with the inhibitors apocynin, FBA, DMPO, 
Catalase and SOD (*p<0.05) (Fig 13A (v-ix), B), suggesting that inhibiting the reactive 
oxygen species might help in attenuating the onset of the TGF-β fibrotic pathway. Similar 
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results of significant increase were observed for the α-SMA and Col 1α immunoreactivity 
in the LEP+PP2Ainh group compared to the control and PP2Ainh only group (*p<0.05) 
(Fig 14A (i-iv), B) (Fig 15A (i-iv), B). The immunoreactivity for α-SMA and Col 1α was 
significantly decreased when the cells were incubated with the inhibitors apocynin, FBA, 
DMPO, catalase and SOD (*p<0.05) (Fig 14A (v-ix), B) (Fig 15A (v-ix), B). 
 
3.4 DISCUSSION 
 
The present study reports a PP2A inhibition-induced role of NOX2 in underlying 
NAFLD leading to the fibrotic phenotype in murine small intestine, a frequent co-
morbidity in diagnostic pathology of the human disease. Further, the intestinal fibrotic 
pathology stems from the higher lactate induced NOX2 activation presumably from higher 
abundance of lactate producing bacteria found in PP2A inhibition as reported by us 
previously. PP2A inhibition, which can be caused due to exposure of environmental 
microcystins mainly through drinking water, consumption of fish and dermal contact poses 
a risk to increased NAFLD cases worldwide. Several research studies reported that 
microcystin could lead to severe damage to the liver, and can also affect the intestines 
through accumulating in the villi regions of the epithelia. Moreover, our studies previously 
suggested that the exposure of microcystin to mice lead to the activation of an 
inflammatory pathway anddisruption of the intestinal barrier thereby forming a leaky gut. 
Microcystin also led to the alteration of the microbiome in phylum, order, family, genus 
and species levels, in which there was a significant increase in the expression of lactate 
producing bacteria Lactobacillus and Enterococcus. Excess lactate production correlated 
to the increase of the serum lactate levels in the mice which were exposed to the PP2A 
inhibitor microcystin. Iatsenko et al. reported that the intestinal NADPH oxidase 2 enzyme 
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was activated by lactate which is produced in drosophila [83]. This led us to study the role 
of lactate in activating NOX2 in the diseased model of non-alcoholic fatty liver disease 
following the microcystin exposure. The lactate thus released is believed to cause the 
activation of the NADPH oxidase 2 enzyme that leads to increased oxidative stress in the 
murine intestine. NOX 2 knockout mice with P47 Phox gene deleted was used to prove the 
role of NOX 2 in activating the downstream signaling pathway leading to the fibrotic 
phenotype. In our previous studies, we have seen that NOX 2 leads to the generation of 
peroxynitrite that causes increased oxidative stress [73]. We also observed that the NOX 2 
activated by the serum lactate following microcystin exposure led to the formation of the 
peroxyntrite species. There was no peroxynitrite generation observed in the P47 Phox 
knockout mice thereby confirming that NOX 2 had a role to play in activating the reactive 
nitrogen species. Use of specific peroxynitrite scavenger phenyl boronic acid (FBA) [84] 
also showed a significant decrease in the peroxynitrite generation, thereby confirming its 
formation.  
This study is of immense significance because it establishes the effects of the PP2A 
inhibitor microcystin in a downstreamTGF-β signaling pathway in the intestinal epithelia 
with lactate induced NOX2 being the primary mediator. The activated NOX 2 enzyme 
leads to the formation of reactive oxygen species that transforms the latent form of TGF-β 
molecule to the latent form [120], which then binds to the TGF-β receptor leading to the 
activation of the fibrotic pathway. An increased TGF-β expression was observed in the 
mice group fed with MCD-HFD and exposed to microcystin, which was significantly 
decreased in the P47 Phox knockout mice group, suggesting a role of NOX 2 derived 
oxidative stress leading to TGF-β production. Activation of the TGF-β receptor 
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phosphorylates the TGF-βR1 receptor complex which in turn can stimulate SMAD 2/3 
phosphorylation and its complex formation with SMAD 4. Protein phosphatase 2A is the 
enzyme that belongs to the family of phosphoprotein phosphatases [121], and majorly acts 
as serine threonine phosphatases [122], is known to dephosphorylate the TGF-βR1 to stall 
the TGF-β activation pathway. Microcystin being a PP2A inhibitor, covalently binds with 
the protein phosphatase 2A and inhibits it from dephosphorylating the TGF-βR1. The TGF-
βR1 therefore remains activated and leads to the phosphorylation of SMAD2/3 and its 
subsequent association with SMAD4, which then translocates to the nucleus. In our results 
we observe that there is a very strong association of SMAD2/3 and SMAD 4 in the mice 
treated with the PP2A inhibitor, which was significantly decreased in the P47 Phox 
knockout group. Finally, we also observed through immunofluorescence staining that there 
was increased levels of α-SMA, Col 1α, vimentin and fibronectin, denoting the formation 
of myofibroblastic cell phenotypes and also extracellular matrix protein deposition in the 
PP2A inhibitor treated group compared to the control group. These levels were 
significantly decreased in the mice with the P47 Phox gene deleted. The fibrotic phenotype 
in the murine intestine was also observed in the treated groups through picrosirius red 
staining, where increased collagen fiber deposition was observed, compared to the control 
group. 
In conclusion, in this study we show that exposure to a PP2A inhibitor microcystin 
under chronic inflammatory conditions of non-alcoholic fatty liver disease can lead to a 
fibrotic phenotype in the murine intestine, through the activation of the NADPH oxidase 2 
enzyme. NOX2 in turn caused the phosphorylation of TGF-βR1 and downstream fibrotic 
pathology presumably by generating redox species dominated by peroxynitrite though 
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independent species such as superoxide radicals or hydrogen peroxide cannot be ruled out. 
Though the evidence points to the direction that PP2A inhibition in NAFLD is mediating 
the fibrotic pathology via higher lactate and subsequent NOX2 activation, more direct 
studies should be conducted to find a concrete role of microbiome alterations, its effect on 
higher lactate production, subsequent NOX2 activation via dysbiosis and disease pathology 
in other inflammatory disorders. By far our present study is first of its kind which tries to 
establish a strong connection between dysbiosis, higher lactate and redox pathology as 
increased emphasis is placed on the role of microbiome alterations in disease. Furthermore, 
our results also show the importance of redox signalling inhibitors and broadly, 
antioxidants as potential candidates for therapeutic applications in chronic inflammatory 
and fibrotic pathology that establish the role of lactate induced NOX2 in such conditions.  
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Figure 3.1 Formalin-fixed, paraffin-embedded 5 μm intestinal slices from lean mouse 
control, wild type mouse control fed with MCD-HFD (NAFLD), wild type mouse group 
fed with chow diet exposed to PP2A inhbitor (CHOW+PP2A inh.) and another NAFLD 
group of mice exposed with PP2A Inhibitor (NAFLD+ PP2A inh.) were used for picrosirus 
red imaging. (A) (i-iv) Representative Picrosirius red stained (PSR) images of intestinal 
sections showed collagen fiber deposition in the small intestine. Images were taken at 20X 
magnification. (B) (v-viii) Representative Immunohistochemistry images of intestinal 
sections depicting Vimentin immunoreactivity in the small intestine of the mice groups. 
Images were taken at 20X magnification. (C)Automatic digital imaging quantification of 
% fibrosis area (*p < 0.05).(D)Morphometric analysis of Vimentin immunoreactivity (*p 
< 0.05). Results were expressed as mean ± SEM. (E) Measurement of serum lactate 
concentration (ng/μL) in the lean mouse control, wild type mouse control fed with MCD-
HFD (NAFLD), chow diet fed wild type mouse group exposed with PP2A inhbitor 
(CHOW+PP2A inh.) and another NAFLD group of mice exposed with PP2A Inhibitor 
(NAFLD+ PP2A inh.) 
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Figure 3.2 Formalin-fixed, paraffin-embedded 5 μm intestinal slices from lean mouse 
control, wild type mouse control fed with MCD-HFD (NAFLD), wild type mouse group 
fed with chow diet exposed to PP2A inhibitor (CHOW+PP2A inh.) and another NAFLD 
group of mice exposed with PP2A inhibitor (NAFLD+PP2A inh.) were used for 
immunofluorescence imaging.  (A) (i-iv) Immunofluorescence images depicting GP91 
phox (red) and P47 phox (green) colocalization, counterstained with DAPI (blue) in LC, 
CHOW+PP2A Inh , NAFLD and NAFLD+PP2A Inh group of mice intestine. Images were 
taken at 20X magnification, (B)(v-viii) Immunofluorescence images depicting the 
proximity ligation (red) of GP91phox and P47phox proteins, counterstained with DAPI 
(blue) in LC, CHOW+PP2A Inh , NAFLD and NAFLD+PP2A Inh group of mice intestine. 
Images were taken at 40X magnification. (C) Morphometric analysis of GP91phox- 
P47phox colocalization events. Y-axis shows % positive immunoreactive area (% ROI) 
(n=3, analysis from three separate microscopic fields) (*p < 0.05). (D) Morphometric 
analysis of GP91phox and P47phox proximity ligation. Y-axis shows % positive 
immunoreactive area (%ROI) (n=3, analysis from three separate microscopic fields) (*p < 
0.05). Results were expressed as mean ± SEM. 
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Figure 3.3 Formalin-fixed, paraffin-embedded 5 μm intestinal slices from lean mouse 
control, wild type mouse control fed with MCD-HFD (NAFLD), wild type mouse group 
fed with chow diet exposed to PP2A inhibitor (CHOW+PP2A inh.), a NAFLD group of 
mice exposed with PP2A inhibitor (NAFLD+PP2A inh.) and another NAFLD +PP2A inh 
group with P47 phox gene knock out (P47phox KO) were used for immunofluorescence 
imaging. (A)(i-v) Immunofluorescence images depicting TGF-β (green) immunoreactivity, 
counterstained with DAPI (blue) in LC, CHOW+PP2Ainh, NAFLD, NAFLD+ PP2Ainh 
and NAFLD+PP2Ainh P47 phox KO group of mice intestine. Images were taken at 20X 
magnification. (B) (vi-x) Immunofluorescence images depicting phospho-TGF-βR1 (red) 
immunoreactivity, counterstained with DAPI (blue) in LC, CHOW+PP2Ainh, NAFLD, 
NAFLD+ PP2Ainh and NAFLD+PP2Ainh P47 phox KO group of mice intestine. Images 
were taken at 20X magnification. (C) Morphometric analysis depicting TGF-β 
immunoreactivity. Y-axis shows % positive immunoreactive area (% ROI) (n=3, analysis 
from three separate microscopic fields) (*p < 0.05). (D) Morphometric analysis depicting 
phospho- TGF-βR1 immunoreactivity. Y-axis shows % positive immunoreactive area (% 
ROI) (n=3, analysis from three separate microscopic fields) (*p < 0.05). Results were 
expressed as mean ± SEM.  
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Figure 3.4 Serum from lean mouse control, wild type mouse control fed with MCD-HFD 
(NAFLD), wild type mouse group fed with chow diet exposed to PP2A inhibitor 
(CHOW+PP2A inh.), a NAFLD group of mice exposed with PP2A inhibitor 
(NAFLD+PP2A inh.) and another NAFLD +PP2A inh group with P47 phox gene knock 
out (P47phox KO) were used for (E) Western blot analysis of phospho- TGF-βR1 and total-
TGF-βR1 protein levels in the serum. Lanes 1–5 represent LC, CHOW+PP2Ainh, NAFLD, 
NAFLD+ PP2Ainh and NAFLD+PP2Ainh P47 phox KO groups respectively. (F) Band 
quantification of the phospho- TGF-βR1 immunoblot in LC, CHOW+PP2Ainh, NAFLD, 
NAFLD+ PP2Ainh and NAFLD+PP2Ainh P47 phox KO groups of mice, data was 
normalized against total- TGF-βR1  (*p<0.05). 
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Figure 3.5 Formalin-fixed, paraffin-embedded 5 μm intestinal slices from lean mouse 
control, wild type mouse control fed with MCD-HFD (NAFLD), wild type mouse group 
fed with chow diet exposed to PP2A inhibitor (CHOW+PP2A inh.), NAFLD group of mice 
exposed with PP2A inhibitor (NAFLD+PP2A inh.) and another NAFLD +PP2A inh group 
with P47 phox gene knock out (P47phox KO) were used for immunofluorescence imaging.  
(A) (i-v) Immunofluorescence images depicting SMAD2/3 (red) and SMAD4 (green) 
colocalization events, counterstained with DAPI (blue) in LC, CHOW+PP2Ainh, NAFLD, 
NAFLD+ PP2Ainh and NAFLD+PP2Ainh P47 phox KO group of mice intestine. Images 
were taken at 20X magnification, (B)(vi-x) Immunofluorescence images depicting the 
proximity ligation (red) of SMAD2/3 and SMAD4 proteins, counterstained with DAPI 
(blue) in LC, CHOW+PP2A Inh , NAFLD, NAFLD+PP2A Inh and NAFLD+PP2Ainh 
P47 phox KO group of mice intestine. Images were taken at 40X magnification. (C) 
Morphometric analysis of SMAD2/3-SMAD4 colocalization events. Y-axis shows % 
positive immunoreactive area (% ROI) (n=3, analysis from three separate microscopic 
fields) (*p < 0.05). (D) Morphometric analysis of SMAD2/3 and SMAD4 proximity 
ligation. Y-axis shows % positive immunoreactive area (%ROI) (n=3, analysis from three 
separate microscopic fields) (*p < 0.05). Results were expressed as mean ± SEM. 
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Figure 3.6 Formalin-fixed, paraffin-embedded 5 μm intestinal slices from lean mouse 
control, wild type mouse control fed with MCD-HFD (NAFLD), wild type mouse group 
fed with chow diet exposed to PP2A inhibitor (CHOW+PP2A inh.), NAFLD group of mice 
exposed with PP2A inhibitor (NAFLD+PP2A inh.) and another NAFLD +PP2A inh group 
with P47 phox gene knock out (P47phox KO) were used for immunohistochemistry and 
immunofluorescence imaging.  (A) (i-v) Immunohistochemistry images depicting α-
smooth muscle actin immunoreactivity, counterstained with DAPI (blue) in LC, 
CHOW+PP2A Inh, NAFLD, NAFLD+PP2A Inh and NAFLD+PP2Ainh P47 phox KO 
group of mice intestine. Images were taken at 20X magnification. (B)(vi-x) 
Immunofluorescence images depicting fibronectin (green), counterstained with DAPI 
(blue) in LC, CHOW+PP2A Inh, NAFLD, NAFLD+PP2A Inh and NAFLD+PP2Ainh P47 
phox KO group of mice intestine. Images were taken at 20X magnification. (C) 
Morphometric analysis of α-SMA immunoreactivity. Y-axis shows % positive 
immunoreactive area (% ROI) (n=3, analysis from three separate microscopic fields) 
(0.01<*p < 0.05). (D) Morphometric analysis of fibronectin immunoreactivity. Y-axis 
shows % positive immunoreactive area (% ROI) (n=3, analysis from three separate 
microscopic fields) (*p < 0.05). Results were expressed as mean ± SEM. 
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Figure 3.7 Intestinal epithelial (IEC-6) cell line was used as control (CONTROL), NAFLD 
was induced in one group of cells with leptin (LEPTIN), a group of cells were treated with 
lactate (LACTATE), and another group of cells were treated with both leptin and lactate 
(LEPTIN + LACTATE). The remaining group of IEC-6 cells were blocked by Apocynin 
(LEP+LAC+APO), FBA (LEP+LAC+FBA), DMPO (LEP+LAC+DMPO), SOD 
(LEP+LAC+SOD), and Catalase (LEP+LAC+CATALASE) and then treated with leptin 
and lactate. (A) (i-iv) Immunofluorescence images depicting GP91 Phox (red) and P47 
Phox (green) colocalization, counterstained with DAPI (blue) in CONTROL, LEPTIN, 
LACTATE, LEPTIN+LACTATE group of IEC-6 cells. Images were taken at 40X 
magnification. (B) Morphometric analysis of GP91Phox- P47Phox co-localized 
immunoreactivity. Y-axis shows % positive immunoreactive area (% ROI) (n=5, analysis 
from five separate microscopic fields) (0.01 < *p < 0.05). (C)(i-ix) Immunofluorescence 
images depicting 3-Nitrotyrosine (green) immunoreactivity, counterstained with DAPI 
(blue) in CONTROL, LEPTIN, LACTATE, LEPTIN+LACTATE, LEP+LAC+APO, 
LEP+LAC+FBA, LEP+LAC+DMPO, LEP+LAC+SOD, and LEP+LAC+CATALASE 
groups of IEC-6 cells. Images were taken at 40X magnification. (D) Morphometric analysis 
of 3-Nitrotyrosine immunoreactivity. Y-axis shows % positive immunoreactive area (% 
ROI) (n=5, analysis from five separate microscopic fields) (*p < 0.05). Results were 
expressed as mean ± SEM. 
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Figure 3.8 Intestinal epithelial (IEC-6) cell line was used as control (CONTROL), NAFLD 
was induced in one group of cells with leptin (LEPTIN), a group of cells were treated with 
lactate (LACTATE), and another group of cells were treated with both leptin and lactate 
(LEPTIN + LACTATE). The remaining group of IEC-6 cells were blocked by Apocynin 
(LEP+LAC+APO), FBA (LEP+LAC+FBA), DMPO (LEP+LAC+DMPO), SOD 
(LEP+LAC+SOD), and Catalase (LEP+LAC+CATALASE) and then treated with leptin 
and lactate. The cell groups were used for immunofluorescence imaging and western blot 
analysis. (A)(i-ix) Immunofluorescence images depicting phospho- TGF-βR1 (red) 
immunoreactivity, counterstained with DAPI (blue) in CONTROL, LEPTIN, LACTATE, 
LEPTIN+LACTATE, LEP+LAC+APO, LEP+LAC+FBA, LEP+LAC+DMPO, 
LEP+LAC+ SOD, and LEP+LAC+CATALASE groups of IEC-6 cells. Images were taken 
at 40X magnification. (B) Morphometric analysis of phospho- TGF-βR1 
immunoreactivity. Y-axis shows % positive immunoreactive area (% ROI) (n=5, analysis 
from five separate microscopic fields) (*p < 0.05). Results were expressed as mean ± SEM.   
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Figure 3.9 Intestinal epithelial cells cells were treated with lactate (LACTATE), and another 
group of cells were treated with both leptin and lactate (LEPTIN + LACTATE). The 
remaining group of IEC-6 cells were blocked by Apocynin (LEP+LAC+APO), FBA 
(LEP+LAC+FBA), DMPO (LEP+LAC+DMPO), SOD (LEP+LAC+SOD), and Catalase 
(LEP+LAC+CATALASE) and then treated with leptin and lactate. The cell lysates were 
collected for (C) Western blot analysis of phospho- TGF-βR1 and total TGF-βR1 protein 
levels in the cell lysates. Lanes 1–9 represent CONTROL, LEPTIN, LACTATE, 
LEPTIN+LACTATE, LEP+LAC+APO, LEP+LAC+FBA, LEP+LAC+DMPO, 
LEP+LAC+ SOD, and LEP+LAC+CATALASE groups of IEC-6 cells respectively. (D) 
Band quantification of the phospho- TGF-βR1 immunoblot in the above mentioned groups 
of IEC-6 cells, data was normalized against total TGF-βR1 (*p<0.05). Results were 
expressed as mean ± SEM. 
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Figure 3.10 Intestinal epithelial (IEC-6) cell line was used as control (CONTROL), NAFLD 
was induced in one group of cells with leptin (LEPTIN), a group of cells were treated with 
lactate (LACTATE), and another group of cells were treated with both leptin and lactate 
(LEPTIN + LACTATE). The remaining group of IEC-6 cells were blocked by Apocynin 
(LEP+LAC+APO), FBA (LEP+LAC+FBA), DMPO (LEP+LAC+DMPO), SOD 
(LEP+LAC+SOD), and Catalase (LEP+LAC+CATALASE) and then treated with leptin 
and lactate. The cell groups were used for immunofluorescence imaging and western blot 
analysis. (A)(i-ix) Immunofluorescence images depicting SMAD2/3 (red) and SMAD4 
(green) co-localization events, counterstained with DAPI (blue) in CONTROL, LEPTIN, 
LACTATE, LEPTIN+LACTATE, LEP+LAC+APO, LEP+LAC+FBA, 
LEP+LAC+DMPO, LEP+LAC+ SOD, and LEP+LAC+CATALASE groups of IEC-6 
cells. Images were taken at 40X magnification. (B) Morphometric analysis of SMAD2/3-
SMAD4 co-localization events. Y-axis shows % positive immunoreactive area (% ROI) 
(n=5, analysis from five separate microscopic fields) (*p < 0.05). Results were expressed 
as mean ± SEM. 
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Figure 3.11 Intestinal epithelial (IEC-6) cell line was used as control (CONTROL), NAFLD 
was induced in one group of cells with leptin (LEPTIN), a group of cells were treated with 
lactate (LACTATE), and another group of cells were treated with both leptin and lactate 
(LEPTIN + LACTATE). The remaining group of IEC-6 cells were blocked by Apocynin 
(LEP+LAC+APO), FBA (LEP+LAC+FBA), DMPO (LEP+LAC+DMPO), SOD 
(LEP+LAC+SOD), and Catalase (LEP+LAC+CATALASE) and then treated with leptin 
and lactate. The cell groups were used for immunofluorescence imaging and western blot 
analysis. (A)(i-ix) Immunofluorescence images depicting α-Smooth muscle actin (red) 
immunoreactivity, counterstained with DAPI (blue) in CONTROL, LEPTIN, LACTATE, 
LEPTIN+LACTATE, LEP+LAC+APO, LEP+LAC+FBA, LEP+LAC+DMPO, 
LEP+LAC+ SOD, and LEP+LAC+CATALASE groups of IEC-6 cells. Images were taken 
at 40X magnification. (B) Morphometric analysis of α-SMA immunoreactivity. Y-axis 
shows % positive immunoreactive area (% ROI) (n=5, analysis from five separate 
microscopic fields) (*p < 0.05). Results were expressed as mean ± SEM. 
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Figure 3.12 Intestinal epithelial (IEC-6) cell line was used as control (CONTROL), NAFLD 
was induced in one group of cells with leptin (LEPTIN), a group of cells were treated with 
lactate (LACTATE), and another group of cells were treated with both leptin and lactate 
(LEPTIN + LACTATE). The remaining group of IEC-6 cells were blocked by Apocynin 
(LEP+LAC+APO), FBA (LEP+LAC+FBA), DMPO (LEP+LAC+DMPO), SOD 
(LEP+LAC+SOD), and Catalase (LEP+LAC+CATALASE) and then treated with leptin 
and lactate. The cell groups were used for immunofluorescence imaging and western blot 
analysis. (A)(i-ix) Immunofluorescence images depicting collagen I (red) 
immunoreactivity, counterstained with DAPI (blue) in CONTROL, LEPTIN, LACTATE, 
LEPTIN+LACTATE, LEP+LAC+APO, LEP+LAC+FBA, LEP+LAC+DMPO, 
LEP+LAC+ SOD, and LEP+LAC+CATALASE groups of IEC-6 cells. Images were taken 
at 40X magnification. (B) Morphometric analysis of collagen I immunoreactivity. Y-axis 
shows % positive immunoreactive area (% ROI) (n=5, analysis from five separate 
microscopic fields) (*p < 0.05). Results were expressed as mean ± SEM  
 
 
86 
 
 
Figure 3.13 Intestinal epithelial (IEC-6) cell line was used as control (CONTROL), NAFLD 
was induced in one group of cells with rat leptin (LEPTIN), a group of cells were treated 
with rat leptin and PP2Ainh (LEP+ PP2Ainh), and another group of cells were treated with 
PP2Ainh only (PP2Ainh only). The remaining group of IEC-6 cells were blocked by 
Apocynin (LEP+ PP2Ainh +APO), FBA (LEP+ PP2Ainh +FBA), DMPO (LEP+ PP2Ainh 
+DMPO), SOD (LEP+ PP2Ainh +SOD), and Catalase (LEP+ PP2Ainh +CATALASE) 
and then treated with rat leptin and PP2A inhibitor, microcystin. The cell groups were used 
for immunofluorescence imaging. (A) (i-iv) Immunofluorescence images depicting GP91 
Phox (red) and P47 Phox (green) colocalization, counterstained with DAPI (blue) in 
CONTROL, LEPTIN, LEP+ PP2Ainh, PP2Ainh only group of IEC-6 cells. Images were 
taken at 40X magnification. (B) Morphometric analysis of GP91Phox- P47Phox co-
localized immunoreactivity. Y-axis shows % positive immunoreactive area (% ROI) (n=5, 
analysis from five separate microscopic fields) (0.01 < *p < 0.05).  
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Figure 3.14 Intestinal epithelial (IEC-6) cell line was used as control (CONTROL), NAFLD 
was induced in one group of cells with rat leptin (LEPTIN), a group of cells were treated 
with rat leptin and PP2Ainh (LEP+ PP2Ainh), and another group of cells were treated with 
PP2Ainh only (PP2Ainh only). The remaining group of IEC-6 cells were blocked by 
Apocynin (LEP+ PP2Ainh +APO), FBA (LEP+ PP2Ainh +FBA), DMPO (LEP+ PP2Ainh 
+DMPO), SOD (LEP+ PP2Ainh +SOD), and Catalase (LEP+ PP2Ainh +CATALASE) 
and then treated with rat leptin and PP2A inhibitor, microcystin. The cell groups were used 
for immunofluorescence imaging. (C) (i-ix) Immunofluorescence images depicting 3-
Nitrotyrosine (green) immunoreactivity, counterstained with DAPI (blue) in CONTROL, 
LEPTIN, LEP+ PP2Ainh, PP2Ainh only, LEP+ PP2Ainh +APO, LEP+ PP2Ainh +FBA, 
LEP+ PP2Ainh +DMPO, LEP+ PP2Ainh +SOD, and LEP+ PP2Ainh +CATALASE 
groups of IEC-6 cells. Images were taken at 40X magnification. (D) Morphometric analysis 
of 3-Nitrotyrosine immunoreactivity. Y-axis shows % positive immunoreactive area (% 
ROI) (n=5, analysis from five separate microscopic fields) (*p < 0.05). Results were 
expressed as mean ± SEM. 
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Figure 3.15 Intestinal epithelial (IEC-6) cell line was used as control (CONTROL), NAFLD 
was induced in one group of cells with rat leptin (LEPTIN), a group of cells were treated 
with rat leptin and PP2Ainh (LEP+ PP2Ainh), and another group of cells were treated with 
PP2Ainh only (PP2Ainh only). The remaining group of IEC-6 cells were blocked by 
Apocynin (LEP+ PP2Ainh +APO), FBA (LEP+ PP2Ainh +FBA), DMPO (LEP+ PP2Ainh 
+DMPO), SOD (LEP+ PP2Ainh +SOD), and Catalase (LEP+ PP2Ainh +CATALASE) 
and then treated with rat leptin and PP2A inhibitor, microcystin. The cell groups were used 
for immunofluorescence imaging. (i-ix) Immunofluorescence images depicting phospho- 
TGF-βR1 (red) immunoreactivity, counterstained with DAPI (blue) in CONTROL, 
LEPTIN, LEP+ PP2Ainh, PP2Ainh only, LEP+ PP2Ainh +APO, LEP+ PP2Ainh +FBA, 
LEP+ PP2Ainh +DMPO, LEP+ PP2Ainh +SOD, and LEP+ PP2Ainh +CATALASE 
groups of IEC-6 cells. Images were taken at 40X magnification. (B) Morphometric analysis 
of phospho- TGF-βR1 immunoreactivity. Y-axis shows % positive immunoreactive area 
(% ROI) (n=5, analysis from five separate microscopic fields) (*p < 0.05). Results were 
expressed as mean ± SEM.  
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Figure 3.16 Intestinal epithelial (IEC-6) cell line was used as control (CONTROL), NAFLD 
was induced in one group of cells with rat leptin (LEPTIN), a group of cells were treated 
with rat leptin and PP2Ainh (LEP+ PP2Ainh), and another group of cells were treated with 
PP2Ainh only (PP2Ainh only). The remaining group of IEC-6 cells were blocked by 
Apocynin (LEP+ PP2Ainh +APO), FBA (LEP+ PP2Ainh +FBA), DMPO (LEP+ PP2Ainh 
+DMPO), SOD (LEP+ PP2Ainh +SOD), and Catalase (LEP+ PP2Ainh +CATALASE) 
and then treated with rat leptin and PP2A inhibitor, microcystin. The cell groups were used 
for immunofluorescence imaging. Immunofluorescence images depicting SMAD2/3 (red) 
and SMAD4 (green) co-localization events, counterstained with DAPI (blue) in 
CONTROL, LEPTIN, LEP+ PP2Ainh, PP2Ainh only, LEP+ PP2Ainh +APO, LEP+ 
PP2Ainh +FBA, LEP+ PP2Ainh +DMPO, LEP+ PP2Ainh +SOD, and LEP+ PP2Ainh 
+CATALASE groups of IEC-6 cells. Images were taken at 40X magnification. (B) 
Morphometric analysis of SMAD2/3-SMAD4 co-localization events. Y-axis shows % 
positive immunoreactive area (% ROI) (n=5, analysis from five separate microscopic 
fields) (*p < 0.05). Results were expressed as mean ± SEM. 
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Figure 3.17 Intestinal epithelial (IEC-6) cell line was used as control (CONTROL), NAFLD 
was induced in one group of cells with rat leptin (LEPTIN), a group of cells were treated 
with rat leptin and PP2Ainh (LEP+ PP2Ainh), and another group of cells were treated with 
PP2Ainh only (PP2Ainh only). The remaining group of IEC-6 cells were blocked by 
Apocynin (LEP+ PP2Ainh +APO), FBA (LEP+ PP2Ainh +FBA), DMPO (LEP+ PP2Ainh 
+DMPO), SOD (LEP+ PP2Ainh +SOD), and Catalase (LEP+ PP2Ainh +CATALASE) 
and then treated with rat leptin and PP2A inhibitor, microcystin. The cell groups were used 
for immunofluorescence imaging. (A)(i-ix) Immunofluorescence images depicting α-
Smooth muscle actin (red) immunoreactivity, counterstained with DAPI (blue) in 
CONTROL, LEPTIN, LEP+ PP2Ainh, PP2Ainh only, LEP+ PP2Ainh +APO, LEP+ 
PP2Ainh +FBA, LEP+ PP2Ainh +DMPO, LEP+ PP2Ainh +SOD, and LEP+ PP2Ainh 
+CATALASE groups of IEC-6 cells. Images were taken at 40X magnification. (B) 
Morphometric analysis of α-SMA immunoreactivity. Y-axis shows % positive 
immunoreactive area (% ROI) (n=5, analysis from five separate microscopic fields) (*p < 
0.05). Results were expressed as mean ± SEM. 
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Figure 3.18 Intestinal epithelial (IEC-6) cell line was used as control (CONTROL), NAFLD 
was induced in one group of cells with rat leptin (LEPTIN), a group of cells were treated 
with rat leptin and PP2Ainh (LEP+ PP2Ainh), and another group of cells were treated with 
PP2Ainh only (PP2Ainh only). The remaining group of IEC-6 cells were blocked by 
Apocynin (LEP+ PP2Ainh +APO), FBA (LEP+ PP2Ainh +FBA), DMPO (LEP+ PP2Ainh 
+DMPO), SOD (LEP+ PP2Ainh +SOD), and Catalase (LEP+ PP2Ainh +CATALASE) 
and then treated with rat leptin and PP2A inhibitor, microcystin. The cell groups were used 
for immunofluorescence imaging. (A) (i-ix) Immunofluorescence images depicting 
Collagen I (red) immunoreactivity, counterstained with DAPI (blue) in CONTROL, 
LEPTIN, LEP+ PP2Ainh, PP2Ainh only, LEP+ PP2Ainh +APO, LEP+ PP2Ainh +FBA, 
LEP+ PP2Ainh +DMPO, LEP+ PP2Ainh +SOD, and LEP+ PP2Ainh +CATALASE 
groups of IEC-6 cells. Images were taken at 40X magnification. (B) Morphometric analysis 
of collagen I immunoreactivity. Y-axis shows % positive immunoreactive area (% ROI) 
(n=5, analysis from five separate microscopic fields) (*p < 0.05). Results were expressed 
as mean ± SEM.
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CHAPTER 4 
 
IMMUNE REGULATION IN MURINE INTESTINE 
FOLLOWING MICROCYSTIN EXPOSURE IN 
UNDERLYING NONALCOHOLIC FATTY LIVER 
DISEASE PATHOPHYSIOLOGY 
 
 
 
 
 
 
 
 
 
 
 
 
 
- Sutapa Sarkar, Diana Kimono, Muayad Albadrani, Ratanesh K Seth, Dipro Bose, 
Ayan Mondal, Punnag Saha, Dwayne E. Porter, Geoff I. Scott, Bryan Brooks, Mitzi 
Nagarkatti, Prakash Nagarkatti, Chatterjee S. Immune regulation in murine 
intestine following  microcystin exposure in underlying nonalcoholic fatty liver 
disease pathophysiology. 
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Abstract: 
Tumorigenesis and cancer progression are one of the main causes for mortality in 
the world, with very limited possibilities of cure. Intestinal tumors are rare and can be 
benign or malignant, though if it remains untreated, it can progress to the cancerous form. 
Studies in our lab have observed that the chronic inflammation due to non-alcoholic fatty 
liver disease leads to an imflammatory bowel disease like phenotype in the gut. In our 
previous studies, we have shown that inhibition of the enzyme protein phosphatase 2A by 
the exposure of an environmental toxin microcystin led to the activation of TGFβ fibrotic 
pathway in murine small intestine. Also, previously we had observed that microcystin 
altered the gut microbiome and exacerbated the intestinal inflammation and barrier 
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dysfunction under the conditions of NAFLD. This led us to investigate the effects of 
microcystin exposure in regulating the immune system which plays an important role in 
tumorigenesis and intestinal cancer, which could be mediated through the NLRP3 
inflammasome complex. Exposure to microcystin led to the activation of NOX2 and 
susequent formation of NLRP3 imflammasome complex in vivo, that led to uncontrolled 
production of IL-18. Elevated levels of the pro-inflammatory cytokines IL-18 and IL-1β 
and subsequent decreased expression of IL-22 binding protein and IL-10 led to the release 
of high levels of IL-17 and IL22, which play an important role in tumorigenesis. Expression 
of the anti-inflammatory IL-10 and the IL-22 binding protein were subsequently increased 
in a P47Phox knockout mice with decreased IL-17A and IL-18 levels compared to the wild 
type treated mouse. Interestingly, the IL-22 levels were decreased to normal which 
indicated the signs of a probable healthy state of the intestines. Hence, this study 
demonstrates an immune regulation following an altered microbiome due to microcystin 
exposure, and the possible induction of an intestinal tumor in the underlying conditions of 
NAFLD. 
 
4.1 INTRODUCTION 
Non-alcoholic fatty liver disease is a worldwide pandemic with no clinical 
cymptoms which affects most of the obese or overweight populations of the western world. 
It is often referred to as the "silent" liver disease, in which there is an accumulation of 
excess fat often accompanied by inflammation. The fat accumulation in the liver is referred 
to as steatosis, which can progress to the more advanced form with excessive scarring, a 
condition known a Non-alcoholic steatohepatitis (NASH). The people suffering from 
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NAFLD can be subjected to certain risk factors including chronic inflammation, stress and 
injury and also cancers. Current studies have revealed that people suffering from NAFLD 
are becoming increasingly prone to liver and gastrointestinal cancers {Sanna, 2016 #40}. 
Muhidin et al. reported that individuals suffering from NAFLD have a higher risk of breast 
and ovarian cancer in women and colorectal cancer in men {Muhidin, 2012 #41}. These 
conditions suggest that it is highly important to study the conditions of NAFLD and its 
comorbidities in an individual, especially if they possess a threat from microcystin 
exposure. The majority of deaths reported in the United States for the patients with NAFLD 
are mostly due to cardiovascular diseases and also gastrointestinal malignancies as reported 
by several studies {Tilg, 2014 #42},{Angulo, 2010 #43}. NAFLD can progress to NASH 
due to exposure with environmental toxins, oxidative stress and several other chemicals. 
Previous research and our lab has studied that Microcystin-LR plays an important role in 
exacerbating the conditions of NAFLD into NASH. Microcystins are highly toxic and very 
low doses are required for causing chronic inflammation and fatalities (12). Microcystin 
(MC-LR) being a potential hepatotoxin primarily affects the liver but it can also affect 
other mammalian organs like heart, kidney, intestines and tissues (13). Also, it is known to 
affect the elderly population who are suffering from the underlying conditions of NAFLD, 
obesity or type 2 diabetes, thereby exacerbating the conditions. Microcystin can be exposed 
to individuals through drinking water, dermal contact and even through recreational 
activities like swimming and bathing.  
Our lab has previously suggested that microcystin exposure to murine NAFLD 
models have led to gut microbiome alteration, formation of inflammasomes and also 
disruption of tight junction proteins {Sarkar, 2019 #44}. The microbiota present in the 
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human gut provides beneficial effects to the host and also regulates the biological functions 
of the host system ({Goncalves, 2016 #46}, {Levy, 2015 #47}. The gut microbiota in the 
intestinal epithelium consist of regulatory T cells, innate lymphoid cells, dendritic cells, 
that maintain the gut barrier function and eliminate the metabolites released from the 
pathogenic bacteria in an inflammatory condition {Hooper, 2015 #48}. The cytokine IL-
18 is considered to be the cytokine which regulates the mechanisms of epithelial repair 
{Harrison, 2015 #49}, though several studies suggest that if the expression of IL-18 
cytokine remains uncontrolled, it may lead to the release of secondary pro-inflammatory 
cytokines. It has been seen that some microbial metabolites like short chain fatty acids are 
required for the IL-18 production and the release of anti-microbial proteins, through 
modulating the NLRP6 inflammasome pathway {Levy, 2015 #50}. Though this hypothesis 
is countered when there is uncontrolled IL-18 signaling which leads to the disruption of 
the intestinal barrier and can lead to an inflammatory bowel disease (IBD) type phenotype 
in the murine intestine {Nowarski, 2015 #51}. A family of lumphocytes innate lymphoid 
cells are regulated by the pro-inflammatory cytokines IL-1β, which are known to be 
released after the activation of an inflammasome {Eberl, 2015 #52}. Once activated they 
can release IL-17A and IL-22 which helps in tissue repair and wound healing {Eberl, 2015 
#53}. However, recent studies have shown that gut microbiome alteration and subsequent 
inflammasome activation may lead to the down-regulation of the IL-22 binding proteins 
(IL-22 BP), which maintains the IL-22 levels in the gut {Huber, 2012 #54}. Similarly, 
normal levels of IL-22 also regulates the normal production of IL-18 required for anti-
inflammatory effects. However, inhibition of IL-22 BP due to the pathogenic and 
inflammatory conditions will lead to elevated levels of IL-22 in the gut, which in turn will 
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lead to the uncontrolled production of IL-18 resulting in the disruption of the intestinal 
homeostasis {Munoz, 2015 #55}. Increased IL-18 levels can further induce the release of 
IL-17A and also IL-22 which promotes tissue inflammation and tumor growth in the 
intestine {Eberl, 2015 #56}, a phenotype which is often observed in the IBD patients.  
This current study investigates the role of microcystin exposure on a mouse model 
under the condition of nonalcoholic fatty liver disease, and the exacerbation of the 
inflammatory phenotype through immune cell regulation. We hypothesized that 
microcystin exposure led to gut microbiome dysbiosis and the activation of NLRP3 
inflammasome, which released pro-inflammatory cytokines compared to the control mice. 
An uncontrolled expression of IL-18 due to the activation of the inflammasome, inhibited 
by the IL-22 binding proteins thereby increasing the epression levels of IL-22 in a feed 
forward loop. Metabolites from the pathogenic bacteria inhibits the anti-inflammatory IL-
10 release from the T regulatory cells leading to the induction of tissue inflammation and 
tumorigenesis through over expression of IL-22 and IL-17A. This study provides a novel 
therapeutic approach by blocking the feed forward loop of IL-18-IL-22 pathway which 
could serve as a treatment for the patients suffering from NAFLD, type 2 diabetes, obesity 
and IBD like phenotype. 
 
4.2 MATERIALS AND METHODS 
 Materials: Microcystin (MC) was purchased from Cayman Chemical Company 
(Ann Arbor, Michigan). Anti-IL17, anti-IL22, anti-IL22 BP, anti-IL10, anti-NLRP3, anti-
caspase1, anti-GP91phox and anti-IL1β primary antibodies were purchased from Abcam 
(Cambridge, MA). Anti-ASC2, anti-p47phox anti-3Nitrotyrosine primary antibody was 
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purchased from Santacruz Biotechnology (Dallas, TX). Species-specific biotinylated 
conjugated secondary antibodies and Streptavidin-HRP (Vectastain Elite ABC kit) were 
purchased from Vector Laboratories (Burlingame, CA). Fluorescence-conjugated (Alexa 
Fluor) secondary antibodies, ProLong Gold antifade mounting media with DAPI were 
purchased from Thermofisher Scientific (Grand Island, NY) and all other chemicals which 
were used in this project purchased from sigma only if otherwise specified. All other 
chemicals were of analytical grade and were purchased from Sigma Chemical Company. 
 
Mouse model:  Pathogen-free, adult (8 weeks old), male C57BL/6J (WT) mice 
(Jackson Laboratories, Ban Harbor, ME) were used in the study. The groups used for the 
experiment were the wild type mice fed with chow diet only (Lean Control), wild type 
mice fed with methionine choline deficient- high fat diet diet only (NAFLD), wild type 
mice fed with chow diet and then exposed to microcystin(Chow+ MC), wild type mice fed 
with methionine choline deficient diet and then exposed to microcystin(NAFLD+MC). The 
total number of animals in each group were assessed based on the calculations that ensured 
enough statistical power of 0.5. There were 8 mice per group that were allocated to their 
respective cages following the procedure of randomization. A total of 32 mice were used 
in the experiments for the paper. All mice experiments were carried out based on the 
approval of the institutional animal ethics committee (IACUC) at the University of South 
Carolina (Assurance number: D16-00028). 
 
Diet-induced NAFLD model: Pathogen-free, male, C57BL/6J (WT) and the 
p47phox gene deleted mice (p47 phoxKO) were fed with methionine choline deficient 
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(MCD-HFD) diet from 8 weeks to 14weeks for diet-induced NAFLD model until the 
experimental dosing was over and were euthanized soon after. The mice weighed about 25 
grams during the time of euthanizing.All mice had ad libitum access to food and water and 
were housed in a temperature controlled room at 23-24°C with a 12-hour light/dark cycle. 
All animals were treated in strict accordance with the NIH Guide for the Humane Care and 
Use of Laboratory Animals and local IACUC standards. We and others have reported 
previously about the role of NADPH oxidase in the pathology of NASH. NADPH oxidase 
is comprised of several cytoplasmic and membrane subunits which align on the membrane 
for an activated enzyme system. P47 phox is the cytosolic subunit of NADPH oxidase and 
a gene deleted P47 phox mouse was used to ascertain the role of the enzyme in the 
pathology of microcystin-induced progression of intestinal comorbidities inNASH.  
 
Exposure of NAFLD mice to environmental toxin Microcystin: Wild-type 
control and gene specific knockout mice (p47phox KO), fed with MCD-HFD diet for 6 
weeks were thenadministered with microcystin (10µg per kg of mouse, 5 dosages per 
week), through the intraperitoneal route for two weeks.The dosage was giveneach 
afternoon at the same time to eliminate any bias in the study.Since this is a sub-chronic 
study, the cumulative effect of the microcystinon inflammatory phenotypes was 
considered. The mice were euthanized at the completion of dosage and serum and small 
intestine tissue was collected for further processing. 
 
Quantitative Real-Time Polymerase Chain Reaction (qRTPCR): mRNA 
expression in intestinal epithelial cell line was examined by quantitative real-time PCR 
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analysis. Total RNA was isolated from the cultured cells and was purified with the use of 
RNeasy mini kit columns (Qiagen, Valencia, CA). cDNA was synthesized from purified 
RNA (1 μg) using iScript cDNA synthesis kit (Bio-rad, Hercules, CA) following the 
manufacturer's standard protocol. Real-time qPCR (qRTPCR) was performed with the 
gene-specific primers using SsoAdvanced SYBR GreenSupermix and CFX96 thermal 
cycler (Bio-rad, Hercules, CA). Threshold Cycle (Ct) values for the selected genes were 
normalized against respective samples internal control (18S). Each reaction was carried out 
in triplicates for each gene and for each sample. The relative fold change was calculated 
by the 2-ΔΔCt method using cells only as a control. Primers were synthesized for Mouse 
IL-18, IL-17, IL-22, Caspase 1, NLRP3 and ASC2. 
 
Immuno-fluorescence microscopy: The deparaffinized intestine tissue section 
from all the mice groups was subjected to epitope retrieval andpermeabilization (0.01% 
triton X-100) followed by blocking with 5% normal serum. Fixed Rat intestinal epithelial 
cells on the cover glass were subjected to permeabilization (0.01% triton X-100) followed 
by blocking with 10% normal serum. Further, both tissue sections and cells were incubated 
with primary antibody (1:250) overnight at 4°C. Species-specific anti-IgG secondary 
antibody conjugated with Alexa fluor 633 (red) and Alexa fluor 488 (green) was used to 
observe the antigen-specific immunoreactivity. Sections were mounted inProLong gold 
antifade reagent with DAPI (counter stain). Morphometric analysis was done using 
CellSens Software from Olympus America.  
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Statistical Analyses: All in vivo experiments were repeated three times with at 
least eight mice per group (N=8); data from each group of eight mice were pooled). The 
statistical analysis was carried out by unpaired t-test and analysis of variance (ANOVA) 
for assessing difference between multiple groups. For all analysis P<0.05 was considered 
statistically significant.For experiments involving 2 groups where distribution of data was 
not clearly parametric, Mann-Whitney U tests were performed with GraphPad Prism 
Software Inc, CA, Version 5.03. For experiments involving 3 or more groups, data were 
evaluated using one-way ANOVA with multiple comparison post hoc analysis. Data are 
expressed as mean ± SEM, or as absolute number or percentage for categorical variables. 
The significance level was set at α = 5% for all comparisons. 
 
4.3 RESULTS 
 Microcystin exposure leads to the activation of NLRP3 inflammasome complex 
in the gut. Previous studies from our lab suggested that exposure to environmental toxins 
led to the increase in pathogenic bacteria and the release of damage and pathogen 
associated molecular patterns (Sarkar S). These DAMPS and PAMPS are known to lead to 
the activation of NLRP3 inflammasome complex in the murine small intestine causing 
inflammation and release of pro-inflammatory cytokines. A group of mice fed with normal 
chow diet was used as the control (CONT) and another group of mice were fed with MCD-
HFD to induce NAFLD (NAFLD). To study the role of Microcystin-LR (MC), we used 
mice fed with chow diet (CHOW+MC) and mice fed with MCD-HFD, followed by a low 
dose of Microcystin (NAFLD+MC). We used immunofluorescence staining to study the 
association of th e two inflammasome subunits in mice small intestine by the number of 
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co-localization events of the red and green channel (yellow spots) (Fig 1A (i-iv), B). 
Results showed that the inflammasome activation was significantly increased in  the 
NAFLD+MC group and the CHOW+MC group compared to the NAFLD only and lean 
mouse control group (*p<0.05) (**p<0.01) (Fig 1A (i-iv), B). The genetic expression of 
NLRP3, ASC2 and Caspase 1 were also examined by quantitative real time PCR. A 20-
fold expression of NLRP3 was observed in the NAFLD+MC group compared to the 
NAFLD only group (**p<0.01), and a 30-fold increase was observed in the CHOW+MC 
group compared to the CHOW only group (*p<0.05) (Fig 2A), suggesting an important 
role of microcystin in exacerbating the inflammatory pathology of the mice small intestine. 
Also, a 2-fold increase in the genetic expression of ASC2 was observed in the NAFLD+MC 
and CHOW+MC group compared to the NAFLD only and lean control group (*p<0.05) 
(Fig 2B). Since, the NLRP3 imflammasome family is comprised of three subunits, we also 
checked the expression of Caspase 1. Results showed that there was a significant increase 
of Caspase 1 in the NAFLD+MC group compared to the control group of mice (*p<0.05) 
(Fig 2C).  
 
Activation of inflammasome due to microcystin exposure leads to the release 
of pro-inflammatory cytokines.  Several studies have reported that the caspase-1 from 
the inflammasome assembly is required to cleave the pro IL-18 and pro IL1β to active IL-
18 and IL1β, leading to its release in the system (ref). Also, studies have observed that 
uncontrolled production of IL-18 might lead to the formation of an inflammatory 
phenotype rather than protective (ref). We measured the gene expression levels of active 
IL-18 through quantitative real time PCR. Our results showed that there was a 35-fold 
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increase of IL-18 production in the NAFLD+MC group compared to the control group 
(**p<0.01) (Fig 2D) and a 10- fold increase in IL-18 release in the NAFLD+MC group 
compared to the NAFLD only group (*p<0.05) (Fg 2D). We also used 
immunofluorescence imaging to study the IL-1β pro-inflammatory cytokine release from 
the small intestine. A significant incresae in IL1β release was observed in the NAFLD+MC 
group compared to the NAFLD group (**p<0.01) (Fig 3A(i-iv), B), which denoted that 
microcystin exposure under the conditions of NAFLD led to a pro-inflammatory surge in 
the mice small intestine. 
 
Microcystin exposure attenuated the expression of anti-inflammatory 
cytokines. Exposure to the toxin microcystin led to the release of elevaled levels of IL-18 
and IL-1β in the mice small intestine, but also attenuates the release of anti-inflammatory 
cytokines like IL-22 binding proteins and IL-10. Previous studies have also suggested that 
decrease in the expression of IL-22 binding proteins, helps in the over production of IL-18 
and can also lead to the release of IL-1β in elevated levels. We used immunofluorescence 
staining to study the levels of anti-inflammatory cytokine expression in mice small 
intestine. Results showed that there was a significant decrease in the expression of IL-22 
binding proteins in the NAFLD+MC group compared to the NAFLD only and the lean 
control group (**p<0.01) (Fig 4A(i-iv), B). Interestingly, there was a marked increase of 
IL-22 binding proteins in the CHOW+MC group compared to the control group, though 
the role microcystin in this group remains unclear. A similar significant decrease of anti-
inflammatory cytokine IL-10 was observed in the NAFLD+MC group and CHOW+MC 
group compared to the NAFLD only and control group of mice (**p<0.01) (Fig 5A(i-iv), 
 
 
104 
 
B). This suggested that under the condition of non-alcoholic fatty liver disease, microcystin 
may attenuate the release of the anti-inflammatory cytokines thereby resulting in the 
exacerbation of the inflammatory phenotype. 
 
Exposure of microsystin leads to the release of cytokines promoting possible 
tumor growth in mice small intestine. As previously studied, exposure of microcystin 
led to the uncontrolled production of IL-18, which inhibited the release of IL-22 binding 
proteins from the dendritic cells. The increased IL-18 was found to activate the innate 
lymphoid cells ILC3 to release elevated levels of IL22 and IL17A, which when remain 
uncontrolled might lead to tumor growth and possible cancers. We used quantitative real 
time PCR and also immunofluorescence staining to study the levels of the IL17 and IL22 
expression in mice small intestine. Our results showed that there was a 4-fold increase in 
the IL17A gene expression in the NAFLD+MC compared to the NAFLD only group and 
also a 3-fold increase in CHOW+MC group compared to the lean control group (**p<0.01) 
(Fig 6B). Results showed a significant increase in the protein expression of IL17A in the 
NAFLD+MC group compared to the NAFLD only and also significant increase in the 
CHOW+MC group compared to the lean control group (**p<0.01) (Fig 6A (i-iv), C). The 
gene expression of IL-22 was increased to 2 folds in the NAFLD+MC and CHOW+MC 
groups compared to the NAFLD only and the control mouse group (*p<0.05) (Fig 7C). 
Similarly, significant increase of the cytokine IL-22 was observed in the NAFLD+MC 
group compared to the NAFLD only and control group of mice (*p<0.05) (Fig 7A (i-iv), 
C), suggesting the possible formation of an intestinal tumor under the inflammatory 
conditions of NAFLD. 
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4.4 DISCUSSION 
 The present research reports a novel inflammatory pathway and the role of the 
altered gut microbiome due to microcystin exposure in exacerbating the imflammatory 
effects in the murine small intestine. It explores the pathway through which the damage 
associated molecular patterns leads to the uncontrolled production of a cytokine, which 
further promotes tumorigenesis and possible intestinal cancer in the future. Previous 
studies have shown that an increase of pathogenic bacteria and release of damage 
associated molecular patterns were observed which exacerbated the inflammatory 
conditions of the murine small intestine. Our lab have observed that microcystin exposure 
led to the alteration of gut microbiome with an increase in pathogenic bacteria. Also, in my 
previous chapters it was seen that the damage associated molecular patterns like HMGB1 
was released into the circulation due to disruption of tight junction proteins and 
endotoxemia. This led us to further investigate the effects of damage associated molecular 
patterns (DAMPS) and pathogen associated molecular patterns (PAMPS) in the murine 
small intestine following microcystin eposure under the conditions of non-alcoholic fatty 
liver disease.  
 It was observed that with the disruption of tight junction proteins and gut leaching, 
the DAMPS and harmful metabolites from the pathogenic bacteria could cross the gut 
barrier and lead to the activation of the NLRP3 inflammasome. The Caspase-1 subunit in 
the NLRP3 inflammasome once activated, can help in the production of IL-18 cytokine in 
the small intestine. It was observed that the expression of Il-18 was elevated to a significant 
level in the NAFLD+MC mice group compared to the lean mouse control group. Now, 
several studies have also suggested that uncontrolled levels of IL-18 can also inhibit the 
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release of IL-22 binding proteins, which are mainly required to keep a check on the IL-22 
cytokine. Our results showed that there was a significant decrease in the expression of IL-
22 binding protein (IL-22 BP) in the NAFLD+MC group compared to the lean mouse 
control group due to the elevated levels of IL-18. Also, an increased expression of the pro-
inflammatory cytokine IL-1β was also observed in the NAFLD+MC group compared to 
the lean mouse control or the NAFLD only group.  
 IL-18 is also known to mediate the release of IL-22 cytokine which is mainly 
required for the production of antimicrobial peptiedes in a state of tissue injury. Also, the 
IL-22 released from the innate lymphoid cells acts in a feed forward loop to keep a balance 
on the levels of IL-18 production. Due to the disruption of the gut barrier, activation of the 
NLRP3 inflammsome and inhibiton of IL-22 binding proteins by over produced IL-18, 
there was a significant increase of IL-22 production in the NAFLD+MC group compared 
to the lean mouse group. Also, the pathogenic bacteria produced due to an altered 
microbiome, inhibited the anti-inflammatory cytokine IL-10, which also kept a check on 
the release of IL-1β. The expression of IL-10 was found to be significantly decreased in 
the NAFLD+MC exposed mice group compared to the lean control or the NAFLD only 
mice group. This led to an increase in the cytokine IL-17A in the NAFLD mice group 
exposed to microcystin compared to the lean mice control. Increase in IL-17A can lead to 
the growth and formation of tumors which can later proceed to intestinal cancer. The 
mechanistic pathway for this research is yet to be elucidated but the study alone holds 
immense significance. The study various insights to target some important factors for 
therapeutic approaches, by controlling the production of IL-18, IL-22 or IL-17A. Also, 
drugs that function in the same mechanistic way as the IL-22 binding proteins, can also 
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pave a way for the therapeutic approach in the situation of an inflammatory condition such 
as NAFLD and its exacerbation by the exposure to environmental toxins. 
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Figure 4.1 Formalin-fixed, paraffin-embedded 5µmintestinal slices from lean mouse 
control (No. of mice per group, N=8), wild type mouse control (NAFLD) (N=8), wild type 
mouse group exposed with Microcystin (CHOW+MC) (N=8) and another NAFLD group 
of mice exposed with Microcystin (NAFLD+MC) (N=8)were used for 
immunofluorescence imaging. (A)(i-iv) Immunofluorescence images in 20X depicting 
NLRP3 (red) and ASC2 (green) colocalization, counterstained with DAPI (blue) in LC, 
CHOW+MC, NAFLD and NAFLD+MC group of mice intestine. (B) Morphometric 
analysis of NLRP3-ASC2 colocalization immunoreactivity. Y-axis shows % positive 
immunoreactive area (% ROI) (n=5, analysis from five separate microscopic fields) (*p < 
0.05) 
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Figure 4.2: mRNA was isolated from wild type mouse control (NAFLD) (N=8), wild type 
mouse group exposed with Microcystin (CHOW+MC) (N=8) and another NAFLD group 
of mice exposed with Microcystin (NAFLD+MC) (N=8) and were used for quantitative 
real time PCR. Quatitative real time PCR involving the genetic expressions of (A) NLRP3 
(B) ASC2 (C) Caspase-1 and (D) IL-18. (*p < 0.05) 
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Figure 4.3 Formalin-fixed, paraffin-embedded 5µmintestinal slices from lean mouse 
control (No. of mice per group, N=8), wild type mouse control (NAFLD) (N=8), wild type 
mouse group exposed with Microcystin (CHOW+MC) (N=8) and another NAFLD group 
of mice exposed with Microcystin (NAFLD+MC) (N=8)were used for 
immunofluorescence imaging. (A)(i-iv) Immunofluorescence images in 20X depicting IL-
1β (red) immunoreactivity, counterstained with DAPI (blue) in LC, CHOW+MC, NAFLD 
and NAFLD+MC group of mice intestine. (B) Morphometric analysis of IL1β 
immunoreactivity. Y-axis shows % positive immunoreactive area (% ROI) (n=5, analysis 
from five separate microscopic fields) (*p < 0.05)  
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Figure 4.4. Formalin-fixed, paraffin-embedded 5µmintestinal slices from lean mouse 
control (No. of mice per group, N=8), wild type mouse control (NAFLD) (N=8), wild type 
mouse group exposed with Microcystin (CHOW+MC) (N=8) and another NAFLD group 
of mice exposed with Microcystin (NAFLD+MC) (N=8)were used for 
immunofluorescence imaging. (A)(i-iv) Immunofluorescence images in 20X depicting IL-
22 BP (red) immunoreactivity, counterstained with DAPI (blue) in LC, CHOW+MC, 
NAFLD and NAFLD+MC group of mice intestine. (B) Morphometric analysis of IL-22 
BP immunoreactivity. Y-axis shows % positive immunoreactive area (% ROI) (n=5, 
analysis from five separate microscopic fields) (*p < 0.05) 
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Figure 4.5. Formalin-fixed, paraffin-embedded 5µmintestinal slices from lean mouse 
control (No. of mice per group, N=8), wild type mouse control (NAFLD) (N=8), wild type 
mouse group exposed with Microcystin (CHOW+MC) (N=8) and another NAFLD group 
of mice exposed with Microcystin (NAFLD+MC) (N=8)were used for 
immunofluorescence imaging. (A)(i-iv) Immunofluorescence images in 20X depicting IL-
10 (red) immunoreactivity, counterstained with DAPI (blue) in LC, CHOW+MC, NAFLD 
and NAFLD+MC group of mice intestine. (B) Morphometric analysis of IL-10 
immunoreactivity. Y-axis shows % positive immunoreactive area (% ROI) (n=5, analysis 
from five separate microscopic fields) (*p < 0.05) 
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Figure 4.6. Formalin-fixed, paraffin-embedded 5µmintestinal slices from lean mouse 
control (No. of mice per group, N=8), wild type mouse control (NAFLD) (N=8), wild type 
mouse group exposed with Microcystin (CHOW+MC) (N=8) and another NAFLD group 
of mice exposed with Microcystin (NAFLD+MC) (N=8)were used for 
immunofluorescence imaging. (A)(i-iv) Immunofluorescence images in 20X depicting IL-
17A (red) immunoreactivity, counterstained with DAPI (blue) in LC, CHOW+MC, 
NAFLD and NAFLD+MC group of mice intestine. (B) quantitative real time PCR for 
IL17A mRNA. (C) Morphometric analysis of IL-17A immunoreactivity. Y-axis shows % 
positive immunoreactive area (% ROI) (n=5, analysis from five separate microscopic 
fields) (*p < 0.05) 
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Figure 4.7. Formalin-fixed, paraffin-embedded 5µmintestinal slices from lean mouse 
control (No. of mice per group, N=8), wild type mouse control (NAFLD) (N=8), wild type 
mouse group exposed with Microcystin (CHOW+MC) (N=8) and another NAFLD group 
of mice exposed with Microcystin (NAFLD+MC) (N=8)were used for 
immunofluorescence imaging. (A)(i-iv) Immunofluorescence images in 20X depicting IL-
22 (green) immunoreactivity, counterstained with DAPI (blue) in LC, CHOW+MC, 
NAFLD and NAFLD+MC group of mice intestine. (B) quantitative real time PCR for IL22 
mRNA. (C) Morphometric analysis of IL-17A immunoreactivity. Y-axis shows % positive 
immunoreactive area (% ROI) (n=5, analysis from five separate microscopic fields) (*p < 
0.05).  
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CHAPTER 5 
 
CONCLUSION 
With the increasing prevalence of obesity in the western and Asian countries, it is 
becoming extremely important to study about the causes as well as the consequences of 
this disease. Obesogens are the chemical compounds which highly disrupts body’s 
regulatory mechanisms. It promotes fat accumulation insulin resistance in the liver thereby 
contributing to be one of the major causes of obesity. Lack of physical exercise and the use 
of improper food habits also contribute to this global pandemic. The consequences of 
obesity involves the onset of different diseases, like cardiovascular and kidney diseases. 
Non-alcoholic fatty liver disease (NAFLD) is one of the major consequences of obesity. It 
arises due to the accumulation of excess fat in the liver which is known as steatosis and 
leads to an inflammatory phenotype in the liver. The condition proves detrimental for 
several individuals since it has no visible symptoms and is often recognized as a 'silent 
liver disease'. The non-alcoholic fatty liver (NAFL) condition can progress to the stage of 
scarring and inflammation, termed as nonalcoholic steatohepatitis (NASH). The 
progression of NAFLD to NASH follows the 'multiple hit hypothesis' where the primary 
hit is due to the steatosis in liver which makes it vulnerable to the second hits like oxidative 
stress, proinflammatory cytokines, adipokines and environmental toxins. The multiple hits 
together can highly damage the liver with excessive scarring, thereby leading to its 
progression to hepatocellular carcinoma. Under these conditions environmental toxins like 
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CCl4 and Bromodichloromethane (BDCM) exacerbate steatohepatitic lesion formation in 
obese liver. Environmental toxins like arsenic and dioxin poses an increased risk to diabetic 
individuals, which is considered to be one of the leading causes of mortality in the U.S. 
Our lab has also previously established that exposure to the water disinfection byproduct, 
bromodichloromethane, leads to nonalcoholic steatohepatitis in a diet induced obese mice 
model. In my research, I have studied about the environmental toxin Microcystin-LR that 
is released from the harmful cyanobacterial blooms. Muayad et al, from our lab established 
that chronic low dose of microcystin can potentiate harmful effects on high fat diet induced 
NAFLD mice liver. The liver underwent inflammation and fibrosis due to the exacerbation 
of the non aalcoholic fatty liver disease to the probable nonalcoholic steatohepatitis. 
Several studies have also found that microcystin is a potent hepatotoxin, but can also affect 
other organs under inflammatory conditions. I have studied the novel mechanisms involved 
in the exacerbation of inflammatory and fibrotic pathology in NAFLD intestines in mice 
following microcystin exposure.  
NADPH oxidase (NOX) plays an important role in the activation of redox pathways 
following an external stress or stimuli. Though the molecular mechanisms involving 
microcystin exposure, NOX activation and the onset of redox downstream signaling 
remains to be explored. Low dose of microcystin exposure exacerbated the progression of 
intestinal disease pathology under the condition of NAFLD. I involved a murine model 
which was fed with 60% kcal high fat diet to induce NAFLD, and then was injected with 
Microcystin through the intraperitoneal route to induce the disease condition. A change in 
the microbiome was observed, with an increase in pathogenic bacteria in the treated group 
compared to the control mice group. The gut dysbiosis was positively associated with the 
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intestinal pathology and NLRP3 inflammasome activation, which is often observed in 
inflammatory bowel disease (IBD) phenotype. Disruption in tight junction proteins and 
systemic endotoxemia was observed in the NAFLD mice treated with microcystin. To 
further confirm that the inflammatory conditions were mainly via the NADPH oxidase 2 
(NOX2) pathway, we used mice that had a genetic deletion of the cytosolic component of 
NOX2 (P47Phox Knockout), induced NAFLD and treated them with microcystin. The 
inflammation and gut barrier disruption was significantly decreased in the knockout mice 
hence leading us to believe that NOX2 had a major role to play in exacerbating the 
inflammatory conditions in the intestine under NAFLD pathophysiology. The cellular 
mechanisms of NOX2 were proven in rat intestinal epithelial cells, which were primed with 
leptin and treated with microcystin. To elaborate the role of NOX enzyme and also 
peroxynitrite to be the main free radical causing the inflammatory pathway, I used the NOX 
inhibitor apocynin, the peroxynitrite scavengen FBA and also the nitrone spin trap DMPO. 
A significant decrease was observed in the inflammasome activation, tight junction proetin 
disruption and also gut leaching in the mice groups exposed to microcystin treated with the 
inhibitor, suggesting an important role of the NOX enzyme in the onset of the diseased 
pathology. 
I also investigated the association between gut microbiome alteration following 
microcystin exposure and the onset of fibrotic pathology in the murine small intestine under 
the inflammatory conditions. Microbiome changes following microcystin exposure lead to 
an increase in lactate producing bacteria along with several other pathogenic bacteria. We 
observed that overproduction of lactate led to the activation of NOX2 that led to generation 
of reactive oxygen species (ROS), which further activated transforming growth factor β 
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(TGF-β) from its latent form to the active form. Activated TGFβ molecule was observed 
to bind to the TGFβ1 receptor, thereby phosphorylating the complex which further 
activated the downstream SMAD protein assembly leading to the transcription of fibrotic 
genes. The novel approach in my study was about the enzyme Protein phosphatase 2A, 
which dephosphorylates the TGFβ1 receptor, to keep a check on the fibrotic signaling. 
Now, microcystin is also known to be a specific inhibitor of PP2A, which when inhibited, 
allowed the lactate-NOX2 induced TGF-β signaling pathway to function in the intestine. 
The mechanisms involving lactate induced NOX2 mediated TGF-β activation were proven 
using rat intestinal epithelial cell line, which was primed with leptin and then exposed to 
microcystin. I have also investigated the release of pathogen associated molecular patterns 
due to the altered gut microbiome and the mechanisms involved in tumor growth. It was 
observed that the uncontrolled production of IL-18 due to the activation of NLRP3 
inflammasome and also the inhibition of anti-inflammatory cytokines by the pathogenic 
bacteria, led to the elevated levels of IL-22 and IL-17A, which is thought to promote 
tumorigenesis in the mice small intestine. 
My research has shown interesting aspects of the development of a diseased 
pathology in the distal organs such as the intestine under the inflammatory conditions of 
non-alcoholic fatty liver disease.  More awareness regarding the present scenario of obesity 
and its increasing threats to mankind should be provided. With increasing number of 
elderly population in the coastal areas, more studies concerning microcystin exposure to 
elderly individals should be carried on to understand the detrimental effects of the toxin to 
different age groups. Therefore, this study provides a novel insight into the various 
mechanisms of microcystin toxicity under a chronic inflammatory condition of NAFLD. 
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